

1 **Single-cell transcriptome landscape of circulating CD4⁺ T cell populations in human autoimmune diseases**

2 **Authors**

3 Yoshiaki Yasumizu^{1,2,3,13}, Daiki Takeuchi^{1,4,13}, Reo Morimoto^{1,13}, Yusuke Takeshima¹, Tatsusada Okuno², Makoto
4 Kinoshita², Takayoshi Morita⁵, Yasuhiro Kato^{5,6}, Min Wang^{7,8}, Daisuke Motooka^{3,9}, Daisuke Okuzaki^{3,9}, Yamami
5 Nakamura¹, Norihisa Mikami¹, Masaya Arai¹, Xuan Zhang⁸, Atsushi Kumanogoh^{3,5,6,10}, Hideki Mochizuki^{2,3}, Naganari
6 Ohkura^{1,11,*}, Shimon Sakaguchi^{1,12,*}

7 **Affiliations**

- 8 1. Department of Experimental Immunology, Immunology Frontier Research Center, Osaka University, Osaka,
9 Japan
- 10 2. Department of Neurology, Graduate School of Medicine, Osaka University, Osaka, Japan
- 11 3. Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research
12 Initiatives (OTRI), Osaka University, Osaka, Japan
- 13 4. Faculty of Medicine, Osaka University, Osaka, Japan
- 14 5. Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine,
15 Osaka, Japan
- 16 6. Department of Immunopathology, Immunology Frontier Research Center, Osaka University, Osaka, Japan
- 17 7. Clinical Immunology Center, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union
18 Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing,
19 China
- 20 8. Department of Rheumatology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine,
21 Chinese Academy of Medical Sciences, Beijing, China
- 22 9. Genome Information Research Center, Research Institute for Microbial Diseases, Osaka University, Osaka,
23 Japan
- 24 10. Center for Infectious Diseases for Education and Research, Osaka University, Osaka, Japan
- 25 11. Department of Frontier Research in Tumor Immunology, Graduate School of Medicine, Osaka University,
26 Osaka, Japan
- 27 12. Department of Experimental Immunology, Institute for Life and Medical Sciences, Kyoto University, Kyoto,
28 Japan
- 29 13. These authors contributed equally to this work

30 * Correspondence

31 **Contact info**

32 Shimon Sakaguchi: shimon@ifrec.osaka-u.ac.jp

33 Naganari Ohkura: nohkura@ifrec.osaka-u.ac.jp

34 **Abstract**

35 CD4⁺ T cells are a key mediator of various autoimmune diseases; however, how they contribute to disease development
36 remains obscure primarily because of their cellular heterogeneity. Here, we evaluated CD4⁺ T cell subpopulations by
37 decomposition-based transcriptome characterization together with canonical clustering strategies. This approach
38 identified 12 independent transcriptional gene programs governing whole CD4⁺ T cell heterogeneity, which can explain
39 the ambiguity of canonical clustering. In addition, we performed a meta-analysis using public single-cell data sets of over
40 1.8M peripheral CD4⁺ T cells from 953 individuals by projecting cells onto the reference and cataloged cell frequency
41 and qualitative alterations of the populations in 20 diseases. The analyses revealed that the 12 transcriptional programs
42 were useful in characterizing each autoimmune disease and predicting its clinical status. Moreover, genetic variants
43 associated with autoimmune diseases showed disease-specific enrichment within the 12 gene programs. The results
44 collectively provide a landscape of single-cell transcriptomes of CD4⁺ T cell subpopulations involved in autoimmune
45 disease.

46 **Keywords**

47 CD4⁺ T cells, autoimmune diseases, single-cell RNA-seq, GWAS

48 **Introduction**

49 Numerous studies have shown that CD4⁺ T cells contribute to autoimmune diseases ^{1,2}, which affect 3-5% of the
50 population and are multifactorial and polygenic ^{1,3}. CD4⁺ T cells exhibit a variety of states (e.g., naive, memory),
51 polarizations (e.g., Th1, Th2, Th17, T follicular helper (Tfh)), and also include a distinct subpopulation engaged in the
52 maintenance of self-tolerance and homeostasis (regulatory T cells (Tregs)) ^{4,5}. While a great deal of effort has been
53 devoted to the detailed classification of CD4⁺ T cells, the complete picture of heterogeneity and its relationship to
54 diseases is still controversial. Furthermore, making consistent assessments across reports is challenging since these
55 reports were based on inconsistent cellular classifications.

56 The recent emergence of single-cell analysis has greatly contributed to the elucidation of cellular diversities through
57 unbiased profiling⁶⁻¹¹. In addition, single-cell RNA-seq (scRNA-seq) is suitable for robust cross-dataset data integration,
58 allowing large-scale investigations¹²⁻¹⁵. On the other hand, conventional clustering and marker gene detection strategies
59 for single-cell analysis possess the following weaknesses: 1. Cell fraction definition requires arbitrary boundaries; 2.
60 Marker genes for clusters can be occupied by redundant genes or uninterpretable genes, such as long noncoding or
61 ribosomal genes, due to the influence of larger cell population structures; 3. Pairwise differentially expressed gene
62 detection cannot capture global gene variation across multiple clusters. Though some studies have attempted to tackle
63 these issues^{16,17}, these difficulties have still hindered the interpretations of complex and poorly demarcated cell
64 populations.

65 Here, we constructed a consensus reference for CD4⁺ T cells in peripheral blood from autoimmune and healthy
66 individuals covering various inflammatory conditions. The reference consists of 18 cell types defined by a conventional
67 clustering strategy and 12 transcriptomic gene programs extracted by conducting decomposition using non-negative
68 matrix factorization (NMF)¹⁸ without boundaries, which overcame the weakness of existing single-cell analyses. The
69 results showed that diverse CD4⁺ T cell features were formed by a combination of 12 independent gene programs. We
70 also illustrated that the gene features obtained by NMF could be projected to other bulk / single-cell RNA-seq data to
71 help interpret various datasets. Using these frameworks to examine the genetic contribution and subsequent changes of
72 CD4⁺ T cells in autoimmunity, we performed a meta-analysis that enrolled over 1.8 million CD4⁺ T cells using published
73 single-cell data of 20 diseases and integrated genome-wide association study (GWAS) statistics for 180 traits with our
74 dataset. These analyses provided a full picture of CD4⁺ T cells in autoimmune diseases from the perspective of
75 phenotypes and genetics.

76 **Results**

77 **Single-cell profiling of peripheral CD4⁺ T cells from healthy and autoimmune donors**

78 To characterize CD4⁺ T cells in various autoimmune properties, we performed single-cell RNA-seq and T cell receptor
79 (TCR)-seq using droplet-based single-cell isolation technology and profiled CD4⁺ T cells, which were collected from
80 three healthy donors, three myasthenia gravis (MG) patients, four multiple sclerosis (MS) patients, and three systemic
81 lupus erythematosus (SLE) patients (Figure 1A; Table S1). After quality control (QC), 103,153 cells were retained and
82 used for the downstream analyses. As the primary layer of clustering (cluster L1), we identified a dynamic differentiation
83 from a naive state via an effector state to a terminally differentiated state. In cluster L1, CD4⁺ naive T cells (Tnaive;
84 CCR7⁺ FAS⁻), CD4⁺ central memory T cells (Tcm; CCR7⁺ FAS⁺), CD4⁺ effector memory T cells (Tem; CCR7⁻ FAS⁺),

85 and CD4⁺ terminally differentiated effector memory T cells (Temra; *FAS*⁺ *CD28*⁻) were observed with distinct gene
86 expression patterns (Figures 1B,D, S1A; Table S2). Tregs were also observed as a distinct cluster with the expression of
87 the master regulator *FOXP3*. Next, we further divided the cells into 18 clusters as the secondary layer, cluster L2
88 (Figures 1C, S1B-D; Table S3). For example, we broke down cluster L1 cells into several T cell subclusters according to
89 well-known transcription factors and chemokine receptors such as Tcm cells into Tfh (Tfh; *CXCR5*, *PDCD1*), Th2
90 (*GATA3*, *CCR4*), Th17 (*RORC*, *CCR6*); Tem cells into Th1/17 (*TBX21*/*Tbet*, *RORC*), Th1 (*TBX21*/*Tbet*); Temra cells
91 into Th1 (Figures 1C,D, S1A-D). Treg cells were divided into three clusters; Treg Naive (*CCR7*), Treg Activated (*ID2*),
92 and Treg Effector (*CCR4*) (Figures 1C,D, S1A-D). In addition, several minor clusters were found, such as Tnaive *MX1*,
93 which preferentially expresses interferon signature genes (Figures 1C,D, S1A,C,D). Transcriptome profiles of each
94 cluster were concordant with bulk RNA-seq data from sorted CD4⁺ T cell fractions provided by the DICE consortium¹⁹
95 (Figure 1E). We found a *CXCR5*⁻ *PDCD1*⁺ cluster occupying 1% in CD4⁺ T cells whose marker genes corresponded to
96 the canonical marker for T peripheral helper (Tph) cells²⁰⁻²² in Tem (Figures S1A,E). The population was annotated as
97 circulating Tph, although a few cells with the expression *CXCR5*⁻ *PDCD1*⁺ were also observed in broader populations,
98 such as Tcm and Temra, (Figures S1A,C,F). Overall, we identified cell populations of peripheral CD4⁺ T cells from
99 healthy and autoimmune states using scRNA-seq.

100 **TCR features across CD4⁺ T cells reflect cellular properties**

101 Because TCR responses shape T-cell functions and differentiation, TCR diversities and overlaps provide useful
102 information for the properties and relationships of populations. Therefore, we analyzed single-cell TCR features
103 sequenced along with gene expression. Clonotype sizes and diversity across cluster L1 populations revealed that Temra
104 was most clonally expanded, followed by Tem, Tcm, Treg, and Tnaive (Figures 1F,G). Similarly, in cluster L2
105 populations, Temra (Th1), Tem (Th1), and Tem (Th1/17) possessed a limited number of clonotypes, whereas Tnaive and
106 Treg Naive maintained diverse clonotype pools (Figure 1H). TCR similarity network showed repertoire sharing between
107 neighboring clusters, Tnaive and Tcm, Tcm and Tem, Tem and Temra, while the distal connection, such as from Tnaive
108 to Temra was not observed, suggesting stepwise development from Tnaive to Tcm, Tem, and Temra (Figures 1I,J). The
109 repertoires were also mutually shared within Tcm cell populations, suggesting the plasticity of T cell polarization against
110 the same epitopes. In addition, Treg Naive and naive conventional T cells (Tconvs) didn't share repertoires, whereas
111 Treg Act and Treg Eff shared repertoires with Tcm populations. We also measured the centrality of TCR networks for
112 each cell type to evaluate the differentiation potential of each cluster. The centrality of Tcm (Th0), Tem (Th1) pre, and
113 Tnaive were consistently high, suggesting that these cells possess the possibility to differentiate into a variety of cell

114 types (Figure S2A). In addition, TCR networks differed depending on the disease states (Figure 1I). Especially the
115 centrality of Tcm (Tfh) and Treg Act were higher in SLE (Figures 1K, S2B). These results indicated that the kinetics of
116 CD4⁺ T cell differentiation varied depending on the disease state.

117 Previous studies have shown that T cells with stronger TCR stimulation within the thymus are more likely to
118 differentiate into Tregs than Tconvs²³. Therefore, Tregs have specific TCR properties, such as hydrophobicity in
119 complementary determining region 3 (CDR3) regions²⁴. We measured the Tregness of TCR β chains (TCR-intrinsic
120 regulatory potential, TiRP score²⁴) and found that the mean TiRP score was higher in Treg cells compared with Tconv
121 cells (Figures 1L,M). On the contrary, Tem (Th1) showed a low TiRP score indicating that Tem (Th1) has experienced
122 the stimulation with non-self antigens. Among Treg cells, Treg Naive and Treg Act showed higher TiRP scores than Treg
123 Eff. It has been thought that naive Tregs contain predominantly thymic differentiated Tregs (tTregs), while effector Tregs
124 are compensated by peripherally differentiated Tregs in addition to tTregs²⁵. This notion was concordant with our
125 observations that naive Tregs had the strongest Treg characteristics in the TCRs and that Treg Act and Eff shared TCRs
126 with Tconvs (Figures 1I,J, S2C). Furthermore, in MS patients, the TiRP scores of the Treg Act were significantly low,
127 reflecting disease-dependent Treg compensation by Tconvs (Figure S2D). Overall, TCR repertoires provided valuable
128 insights into T cell characteristics and relationships during the differentiation.

129 **Decomposition of cellular programs using NMF**

130 Next, we attempted to identify cellular programs within and across cell types. We noticed that conventional clustering
131 and marker gene detections could fail to capture meaningful clusters and genes. For example, differentially expressed
132 genes in our reference included overlapping genes among Th1 cell populations and nonsense genes in Tnaive cells,
133 suggesting the conventional marker gene detection is insufficient for CD4⁺ T cells (Figure S1C). We suspected that
134 artificially delineating in the clustering process is unsuitable for a gradual population such as CD4⁺ T cells. In addition,
135 because marker gene detections are performed by pairwise comparison, global representations across cell types cannot be
136 detected. To overcome these limitations, we applied non-negative matrix factorization (NMF)¹⁸ to normalized gene
137 expression of our scRNA-seq data and unbiasedly dissected gene expression profiles into a gene feature matrix \mathbf{W} and a
138 cell feature matrix \mathbf{H} (Figure 2A). To determine the number of components, we assessed the explained variances and
139 maximum inter-component correlations and selected 12 for the number of components as they kept sufficient information
140 and were not redundant (Figure S3A; methods). Based on the gene feature profiles and the enriched pathways, we
141 annotated the NMF components (Figures 2B-D, S3B; Table S4,5). Several factors were related to T-cell polarization,
142 such as Treg-Feature (Treg-F, NMF1; genes with high weights; *IKZF2*, *FOXP3*), Th17-F (NMF 2; *RORC*, *CCR6*),

143 TregEff/Th2-F (NMF5; HLA class II genes, *CCR10*, *CCR4*), Tfh-F (NMF6; *TIGIT*, *CXCR5*), Th1-F (NMF11; *GZMK*,
144 *EOMES*, *CXCR3*), and differentiations such as Naive-F (NMF3; *CCR7*, *TCF7*), Central Memory-F (NMF8; *S100A8*,
145 *ANXA1*), and Cytotoxic-F (NMF0; *GZMB*, *NKG7*). NMF5 was enriched in both Th2 and Treg Eff, suggesting that
146 effector Treg cells and Th2 cells may be controlled by the shared program as previously suggested²⁶ (Figure 2B). NMF6
147 (Tfh-F) also demonstrated moderate activity in Treg Act, suggesting an overlap between Treg Act and T-follicular
148 regulatory (Tfr) cells²⁷ (Figure 2B). NMF11^{high} cells were enriched in Tem (Tph), Tem (Th1), and Tem (Th1/17) cells
149 showing a wide range of Th1ness gene usage across these subtypes. Moreover, NMF7 was a type I interferon signature
150 gene component enriched in Tnaive *MX1* (Figures 1C, S3B). Intriguingly, NMF10 captured a global feature across cell
151 types consisting of AP-1 family genes (*JUNB*, *FOS*), *NFKBIA*, *CD69*, and *CXCR4* (Figure 2D). This feature was
152 concordant with tissue-homing T-cells observed in the thymoma of MG patients⁷ and the central nervous system of
153 neurodegenerative disease patients²⁸, and was labeled as Tissue-F. NMF4 (Act-F) was related to *IL7R* signaling, which
154 is an essential survival and differentiation signal²⁹. The proportion of explained variance (Evar) showed the most drastic
155 variations in the peripheral CD4⁺ T cells were differentiation from Tnaive to Tem, Tem, and Temra, and the polarizations
156 were relatively smaller changes and independent of the differentiation programs (Figure 2B). Altogether, NMF
157 succeeded in the decomposition of peripheral CD4⁺ T cell gene programs into 12 components and showed that complex
158 CD4⁺ T cell populations were represented by a simple combination of the 12 components.

159 **NMF projection enables fast interpretation of various CD4⁺ T transcriptome datasets**

160 One of the biggest challenges in single-cell analysis is the integration of datasets. To achieve a simple integration, we
161 expanded the NMF framework to allow the projection of the pre-computed gene feature matrix onto other datasets by
162 developing a bioinformatics tool, NMFproj (Figure 2A, <https://github.com/yyoshiaki/NMFprojection>). To measure how
163 the NMF features explain the variance of the query dataset, we introduced a QC metric named the proportion of
164 overlapped highly variable genes (POH) (Figure S3C). A low POH indicates that the query data set has much variability
165 other than the NMF features evaluated by NMFproj. We applied NMFproj to various datasets to validate the scalability
166 (Supplementary Note). Analysis of bulk RNA-seq of sorted peripheral CD4⁺ T cells provided by the DICE project¹⁹
167 demonstrated that each fraction was well represented by the 12 NMF gene features (POH: 0.272, Figure S3D). Miyara
168 classification³⁰, which classified CD4⁺ T cells into Fr. I to Fr. VI by the expression of CD45RA and CD25, was re-
169 evaluated by NMFproj and showed that Fr. III (CD45RA⁻ CD25^{int}) has Th17 type characteristics in line with the original
170 report³⁰ (POH: 0.542, Figure S3E, Supplementary Note). In addition, profiling of circulating Tph cells²⁰ revealed that
171 Tph cells possessed both NMF6 (Tfh-F) and NMF11 (Th1-F) in concordance with Tem (Tph) we defined as cluster L2
172 (POH: 0.134, Figure S3F, Supplementary Note). We also attempted to utilize NMFproj for the QC of *in vitro* induced

173 Treg (iTreg) cells of mouse³¹ and found that iTreg cells induced in optimized conditions for enhancing Treg
174 functionality showed higher NMF1 (Treg-F) values than conventional iTreg cells (POH: 0.182, Figure S3G,
175 Supplementary Note). We also applied NMFproj to scRNA-seq datasets of cross-tissue immune cells³² (Figure S5, POH:
176 0.560 in CD4⁺ T cells, Supplementary Note), pan-cancer tumor-infiltrating CD4⁺ T cells¹⁵ (Figure S4A, POH: 0.530,
177 Supplementary Note), and mouse splenocytes³³ (Figure S4B, POH: 0.394, Supplementary Note), achieving robust
178 interpretations of cellular features in various conditions. Furthermore, cell-specific qualitative changes have been
179 reported in autoimmune diseases, such as Treg dysfunction in SLE³⁴, and we hypothesized that NMFproj could be used
180 to detect these changes in individual cell populations. To test this, we applied NMFproj to bulk RNA-seq data of sorted
181 peripheral CD4⁺ T cell fractions from various autoimmune patients³⁵. NMFproj detected a subset-specific gene program
182 robustly even in a variety of autoimmune disease conditions (Figure S6A, Supplementary Note). The results showed cell-
183 type wide enhancement of NMF7 (IFN-F) in SLE and mixed connective tissue disease (MCTD) and hampered NMF1
184 (Treg-F) in Fr.I nTregs (CD45RA⁺ CD25⁺) in SLE patients as previously reported³⁴ (Figure S6B). These results
185 indicated that NMFproj could robustly assess the qualities of CD4⁺ T cells in various tissues and disease states,
186 regardless of bulk/single cell or human/mouse.

187 **Meta-analysis of CD4⁺ T cells in various autoimmune diseases**

188 To extend CD4⁺ T cell profiling to various autoimmune and infectious diseases, we performed a meta-analysis using
189 publicly available single-cell data^{6,8,36-57}. We integrated publicly available datasets with two strategies: 1) quantitative
190 evaluation of cell frequencies by mapping to our reference and 2) evaluation of qualitative changes per cell type using
191 NMFproj. We extracted CD4⁺ T cells from peripheral blood mononuclear cells (PBMCs) using Azimuth⁵⁸ and then
192 mapped them to our reference using Symphony¹⁴ (Figure 3A, the pipeline is available at
193 <https://github.com/yyoshiaki/screfmapping>). We collected 1,809,668 CD4⁺ T cells collected from 647 cases and 306
194 controls from 25 projects (Figures 3B, S7A; Table S6). For quality assurance, only datasets in which both HC and
195 patients were present and at least 3 cases were included were used. As a prominent change, Tnaive decreased, and Temra
196 increased in various autoimmune diseases (Figure S7B; Table S7). It has been reported that Temra increased in the
197 peripheral blood of rheumatoid arthritis (RA), MS, ulcerative colitis (UC), and Crohn's disease (CD) patients⁵⁹⁻⁶², which
198 was consistent with the present data. Kawasaki disease and Type 1 diabetes (T1D) were exceptions among autoimmune
199 diseases, with a slight increase in Tnaive and no significant change in Tcm, Tem, and Temra (Figure S7B), as reported
200 previously^{63,64}. At cluster L2 resolution, we found that Tnaive *MX1* increased in COVID-19, SLE, T1D, and primary
201 Sjögren syndrome (pSS) patients (Figure 3C). The type I IFN response is essential for viral elimination and has been
202 reported to be associated with COVID-19 pathology⁶⁵ and also known to be associated with SLE⁶⁶, pSS⁶⁷, and T1D⁶⁸.

203 Our meta-analysis could detect these effects as the increase of Tnaive *MX1*. Moreover, in our meta-analysis, Tcm (Th17)
204 was increased in various diseases, including previously reported diseases such as MG⁶⁹, MS^{70,71}, and psoriasis⁷².
205 Regarding Tregs, we reported that Fr. II (CD45RA⁻ CD25⁺) is increased in sarcoidosis, while Fr. I and III are increased
206 in active SLE³⁰. Another group reported an increase of Tregs in pSS⁷³. In concordance with these observations, Treg
207 increased in SLE, neurosarcoidosis, sarcoidosis, and pSS, especially for Treg Eff in neurosarcoidosis and for Treg Act
208 and Treg Eff in SLE patients (Figures 3C, S7B). Interestingly, the acute infection response to COVID-19 showed an
209 increase in Tnaive, whereas influenza infection showed an increase in Temra. We also found age-dependent Tnaive
210 decrease and Temra, Treg Eff increases concordant with previous reports⁷⁴ (Figure 3C). Sex differences in immunity are
211 critical, especially for autoimmune diseases, because 80% of autoimmune disease occurs in females⁷⁵. Previous reports
212 have addressed several changes in females, such as the increase of recent thymic emigrants⁷⁶ and greater activation
213 responses by *in vitro* stimulation⁷⁷. As for gender differences, we observed a decrease in Tcm (Th2), Tem (Th1/17),
214 Temra (Th1), and Treg Eff and an increase in Tnaive Act, Tnaive *MX1*, Tnaive *SOX4*, Tem (Tph), and Treg Naive in
215 females. These alterations depending on diseases, gender, and age were also observed as specific distributions on the
216 PCA plot (Figures 3D-F, S7C,D). Overall, we profiled numerical features of CD4⁺ T cells in broad autoimmune status,
217 age, and gender.

218 Next, to measure the quality changes in autoimmune diseases, we applied NMFproj to the datasets and investigated
219 NMF cell feature changes in each cluster L2 population (Figures 3G, S8B, S9; Table S9). The strongest skews were
220 enriched in NMF7 (INF-F) in SLE and COVID-19 patients in a cell-type-wide manner. We also found that even neutral
221 populations such as Tnaive, Tnaive (Act), and Tcm (Th0) showed disease-specific propensities. For example, NMF0
222 (Cytotoxic-F) increased in RA, MS, and pSS, NMF10 (Tissue-F) was increased in MS, COVID-19, SLE, and
223 neurosarcoidosis, while NMF3 (Naive-F) decreased in a broad range of autoimmune diseases. In Treg cells, NMF1
224 (Treg-F) decreased in T1D, MG, and MS, indicating the dysfunction of Treg in these diseases independently of the
225 number of Treg cells. Age-dependent increases of NMF8 (Cent. Mem.-F) and NMF4 (Act-F) were also observed. In
226 females, NMF4 (Act-F) was enhanced broadly. The results of qualitative and quantitative changes were consistent with
227 previous reports, demonstrating the robustness of our catalog. For example, it has been reported that among CD4⁺ T cells,
228 an increase of CXCR4⁺ Tnaive is the dominant change in COVID-19 infection⁷⁸. This is concordant with the result of
229 our meta-analysis showing an increase in Tnaive and an increase in NMF10 (Tissue-F), which contains *CXCR4* as the
230 feature gene (Table S4), specifically in Tnaive cells. Other findings, such as the upregulation of an activation molecule,
231 CD69, which was the feature gene of NMF10 (Tissue-F), in MS and SLE⁷⁹, and the reduction of effector Tregs and their
232 decreased function in T1D⁸⁰, are also consistent with our meta-analysis. In conclusion, by meta-analysis, in addition to

233 quantitative changes, we identified qualitative changes depending on the disease, sex, and age at a resolution that is
234 difficult to observe in existing methodologies.

235 **Autoimmune states are predictable only from peripheral CD4⁺ T profiles**

236 Given that each autoimmune disease disorder possessed a characteristic CD4⁺ T cell profile, we hypothesized that
237 disease status might be predicted solely from CD4⁺ T profiles by utilizing machine learning techniques and our
238 autoimmune-wide scRNA-seq dataset. To confirm this, we created three models for the prediction of disease status. The
239 first model took the frequency of each cell population in cluster L2, the second model took the cellular features of the
240 NMF in subsets, and the last model took both as input parameters (Figure 3H). We note that, for NMFproj features, only
241 Tnaive and Tcm (Th0) cell features, which were affected by various conditions as discussed previously (Figures 3G,
242 S8A), were used to avoid over-fitting. First, binary classification models were constructed for SLE, COVID-19, and MS
243 to distinguish between certain diseases and healthy individuals using logistic regression where equal numbers of diseased
244 and healthy subjects were used for the training, and the models were evaluated using samples from independent projects
245 from these used for the training (Figure 3I). SLE and COVID-19 yielded relatively good predictions from cell
246 frequencies alone (AUC: 0.84, 0.82 in SLE and COVID-19, respectively). NMF cell features alone also could predict
247 SLE and COVID-19 well (AUC: 0.94, 0.85 in SLE and COVID-19, respectively), and the perdition using both cell
248 frequencies and NMFproj values further improved accuracy (AUC: 0.94, 0.91 in SLE and COVID-19 respectively). For
249 MS, for which hematological biomarkers have not yet been well-established, prediction from cell frequencies or from
250 NMFproj values alone was not successful (AUC: 0.61, 0.47 in cell frequency and NMFproj respectively), while both cell
251 frequencies and NMFproj values resulted in better predictions (AUC: 0.75) than previous reports ⁸¹. Next, we built
252 multiclass classification models that more closely resemble real-world clinical practice. The multiclass classification was
253 assumed to be a more difficult task due to the similarities among autoimmune diseases and the imbalance of training
254 sample sizes. We trained a gradient boosting model with 5-fold cross-validation on data from 714 samples from 8
255 diseases or healthy for which at least ten samples were available for training and then evaluated the model using the data
256 from the independent dataset (Figures S8B,C). The model trained only by cell frequencies or by NMFproj values could
257 predict COVID-19, SLE, HC, and MS (Area Under the Precision-Recall Curve (PR-AUC): 0.72, 0.68, 0.48, 0.12 in the
258 cell frequency model and 0.91, 0.75, 0.47, 0.35 in the NMFproj model, for COVID-19, SLE, HC, and MS respectively),
259 and the model trained by both cell frequencies and NMFproj values in Tnaive and Tcm (Th0) was marked with superior
260 accuracy (PR-AUC: 0.92, 0.69, 0.50, 0.33 for COVID-19, SLE, HC, and MS respectively). These results highlight that
261 the disease-specific changes in CD4⁺ T cells, both in terms of quantitative and qualitative alterations, contribute to the
262 prediction of disease status.

263 **Partitioned heritability of autoimmune diseases on CD4⁺ T cell NMF features**

264 We examined the association between CD4⁺ T characteristics and genetic factors for each disease and trait. Studies using
265 GWAS statistics have reported associations between autoimmune diseases and immune cells ^{1,82}. In particular, stratified
266 linkage disequilibrium score regression (S-LDSC) has revealed the association between CD4⁺ T cells and autoimmune
267 diseases by stratifying the heritability of polygenic autoimmune diseases by genetic features ^{83,84}. Since we captured
268 elaborate CD4⁺ T cell features, we investigated which of these features were associated with each trait using the S-LDSC
269 framework. In addition to the cell-type specific genes of cluster L2, 12-dimensional features extracted by NMF were
270 used as genetic features. The Roadmap Enhancer-Gene Linking (Roadmap) and Activity-By-Contact (ABC) strategies
271 introduced in the sclinker framework ⁸⁵ were used for linking genes and SNPs. Among 180 traits, autoimmune diseases
272 showed significantly high enrichment in NMF features ($p=8.51 \times 10^{-12}$), suggesting autoimmunity is closely associated
273 with CD4⁺ T cells (Figure 4A). Cross-sectional disease association revealed that many diseases, such as Inflammatory
274 bowel disease (IBD), RA, and MG, have an enrichment of heritability on NMF1 (Treg-F) (Figure 4B). By focusing on
275 the most accumulated factors for each disease, we found that autoimmune diseases can be divided into several groups.
276 For each disease, the most enriched gene features were observed as; NMF1 (Treg-F): RA, UC (deLange),
277 hypothyroidism; NMF2 (Th17-F): CD (deLange), IBD (deLange), MG; NMF5 (TregEff/Th2-F): celiac disease, T1D;
278 NMF7 (IFN-F): SLE, primary biliary cirrhosis; NMF10 (Tissue-F): MS, psoriasis. In MS, accumulation was observed in
279 various features, including NMF2 (Th17-F) and NMF11 (Th1-F). The heritability of each autoimmune disease was
280 accumulated in several factors, suggesting that autoimmune diseases have multiple susceptibilities. In other traits, weak
281 accumulation on NMF1 (Treg-F), NMF2 (Th17-F), and NMF11 (Th1-F) was common in COVID-19 in both severe
282 symptoms and infection, while NMF7 (IFN-F) was infection-specific (Figure S10A). Lymphocyte counts were also
283 susceptible to NMF4 (Act-F) (Figure S10A). We also examined enrichment in cell-type-specific genes. Similar
284 enrichment patterns, such as Treg Naive in most autoimmune diseases and Tnaive *MX1* in SLE, were observed, while
285 caution should be taken as marker gene detection is not optimal for CD4⁺ T cells as in the previous section (Figure S10B).
286 Taken together, we comprehensively profiled heritability enrichment on CD4⁺ T cell gene features across autoimmune
287 diseases.

288 **Partitioned heritability is associated with qualitative and/or quantitative changes in CD4⁺ T in a disease-specific
289 manner**

290 Lastly, we compared partitioned heritability and observed changes in CD4⁺ T in terms of quantity (cell frequency) and
291 quality (NMFproj) to assess the genetic effect on phenotypic changes (Figure 5A). We first investigated the correlation
292 between enriched heritability and changes in cell frequency and NMF features for diseases that were enrolled in our

293 analysis for both GWAS and meta-analysis. We found several patterns depending on the disease (Figure 5B). First, in
294 MG and psoriasis, both changes in cell frequency and NMF feature correlated with heritability accumulation. In severe
295 COVID-19 (COVID19-A, COVID19-B) and RA, the correlation was mainly observed with changes in quality only. SLE,
296 celiac disease, UC, and SARS-CoV-2 infection (COVID19-C) showed poor correlation with cell frequency.

297 Next, we examined MS, MG, and SLE, whose samples were collected in this study, in more detail (Figure 5C). In MG,
298 NMF2 (Th17-F), which accumulated heritability most significantly, was increased in Tcm (Th17) and Tem (Th1/17) in
299 correlation with genetic factor accumulation, and the cell frequency was also correlated with genetic factors (Figures 5C,
300 S9). On the other hand, NMF1 (Treg-F), which showed the next highest accumulation of heritability, was negatively
301 correlated with the genetic effect and lower in Treg cells (Figure S9), indicating that the dysfunction of Treg cells might
302 be enhanced by the genetic effect. In MS, the highest heritability accumulation was observed in NMF10 (Tissue-F). This
303 factor was increased in all cell populations without cell specificity, resulting in a low correlation with the heritability.
304 SLE susceptibility was most accumulated in NMF7 (IFN-F). In our meta-analysis, an enhancement of NMF7 (IFN-F)
305 was observed in all cell populations, especially in Tnaive *MX1*. Overall, our study cataloged heritability enrichment and
306 phenotypic changes across autoimmune diseases, enabling elucidation of the disease-specific effect of underlying genetic
307 factors on CD4⁺ T cell phenotypes.

308 **Discussion**

309 The classifications and characterizations of CD4⁺ T cells have been challenging, with cellular heterogeneity being a
310 major obstacle⁴. In this study, by performing single-cell analysis on CD4⁺ T cells from autoimmune and healthy subjects,
311 we succeeded in mutually exclusive and collectively exhaustive subtype identifications of peripheral CD4⁺ T cells.
312 Moreover, in contrast to the conventional dualistic comparisons such as Th1 vs. Th2 and Treg vs. Th17, the NMF-based
313 decomposition revealed that CD4⁺ T cells are formed by a combination of 12 features rather than simple contradistinction.
314 While qualitative profiling by NMF was not suitable for numerical evaluation, it allowed for a more robust assessment of
315 gradual cell populations. Moreover, our results can also be extrapolated for other single-cell and bulk RNA-seq studies
316 by using a label transfer and the projection of NMF features.

317 These analytical frameworks also allowed us to perform autoimmune-wide single-cell meta-analyses and integration of
318 CD4⁺ T cell features with GWAS. As a result, we comprehensively cataloged CD4⁺ T cell alterations in 20 diseases,
319 providing a valuable resource for a broad range of disease research. The assessment of qualitative changes through
320 NMFproj enabled us to explore biological insights, such as Treg functional abnormalities, that were previously
321 unattainable using cytometry. Furthermore, the decomposition of gene programs using NMF was beneficial not only for

322 T-cell profiling but also for interpreting GWAS results. We found that genetic factors can have both disease-specific and
323 cross-disease impacts on autoimmune conditions. The accumulation of heritability on Tregs across diseases and the
324 disease specificity of other features may be potential clues for future therapeutic development.

325 By examining genetic factors, CD4⁺ T cell changes, and TCR characteristics in a disease-specific manner, we gained
326 valuable insights into various diseases. For example, MG is caused by autoantibodies against the neuromuscular junction,
327 with germinal center responses involving Tfh cells and B cells within the thymus ^{7,86}. While Th17 function enhancement
328 has been reported in MG ^{69,87}, we also observed a heritability enrichment in NMF2 (Th17-F), suggesting that tissue
329 damage by Th17 cells may contribute to symptom completion and persistence. In MS, we observed an increase in
330 NMF10 (Tissue-F) and heritability enrichment in addition to the previously known Th17 and Th1 increase and functional
331 enhancement ^{70,71,88}. These results suggested that a strong tissue inflammatory response is involved in MS. These results
332 emphasized that the tissue-specific gene program centered on the AP-1 family may be a novel MS-specific therapeutic
333 target ⁸⁹. Additionally, in MS, while Treg Eff slightly increased, the quality of Treg cells in terms of transcriptome and
334 TCR was low, indicating that the compensation of Tregs from Tconvs is an explanation for Treg dysfunction in MS ⁹⁰. In
335 SLE, our analysis of heritability enrichment and qualitative alterations supported the traditional belief that Type I IFN is
336 central to the disease ⁹¹. Type I IFN drives differentiation into Tregs and Th1 cells ^{92,93}, and our result suggested that the
337 pleiotropic effect of Type I IFN contributed to the complicated cell frequency changes observed in this study.

338 Furthermore, TCR overlaps between Tcm (Tfh) and Treg Act were observed specifically in SLE, suggesting potential
339 Treg-Tfh plasticity in SLE similar to reported Tfh-Treg plasticity under certain inflammatory conditions ^{94,95}. We
340 identified distinct CD4⁺ T cell responses between COVID-19 and influenza infection, with an increase in Tnaive cells in
341 COVID-19 and Temra cells in flu. This divergence may reflect differences between pre-trained immunity to influenza
342 and initial responses to SARS-CoV-2, as most COVID-19 samples were collected before the vaccine rollout. In addition,
343 our meta-analysis revealed sex and age-related CD4⁺ T cell changes, with new observations such as increased Tnaive
344 MX1 and Tem (Tph) in females, potentially contributing to gender differences in autoimmune disease incidence. Thus,
345 our study highlights the CD4⁺ T cell features of each disease and condition, providing new insights for consideration.

346 Additionally, this study created a comprehensive CD4⁺ T cell catalog across various diseases for the first time, providing
347 the opportunity to tackle the challenging task of assessing whether disease prediction is feasible using CD4⁺ T cell
348 profiles. The machine learning model showed that disease status could be predicted only from CD4⁺ T profiles. Although
349 we still could not collect samples abundantly for the model training for clinical applications, this study showed the
350 potential for capturing undiagnosed autoimmune diseases from cellular conditions in the future. The predictability also

351 indicated that changes in CD4⁺ T profiles clearly characterized each disease, emphasizing the importance of fine-tuned
352 treatments for individual diseases.

353 In our discussion, it is important to address a key limitation of our study, which is that it focused on peripheral blood
354 and did not evaluate tissue alterations, such as barrier tissue-specific programs⁹⁶. This might be the reason that we could
355 not capture some known vital phenomena for CD4⁺ T cells, such as anergy and exhaustion. On the other hand, the NMF
356 defined in peripheral blood fitted well with tissue CD4⁺ T cells and tumor-infiltrating T cells, suggesting that peripheral
357 blood can be used as a snapshot of complex T cell responses and that these profiles are applicable to tissues.

358 Collectively, we constructed the frameworks for extracting the CD4⁺ T cell programs, enabling a comprehensive
359 interpretation of CD4⁺ T cells. Moreover, the landscape of disease-specific CD4⁺ T cell alterations and genetic effects
360 provides biological insights for potential precision medicine.

361 **STAR Methods**

362 **Human samples**

363 The study using human samples was reviewed and approved by the Research Ethics Committee of Osaka University
364 and carried out in accordance with the guidelines and regulations. Human samples were collected under approved Osaka
365 University's review board protocols: ID 708-10. Written informed consent was obtained from all donors.

366 **Cell preparation and sequencing of scRNA-seq**

367 From blood collected using heparin-coated tubes, we first collected PBMCs using Ficoll-Paque (Cytiva). PBMCs were
368 washed, blocked with Fc Receptor Binding Inhibitor Polyclonal Antibody, Functional Grade, eBioscienceTM (Thermo
369 Fisher Scientific), and stained with FITC-labeled anti-CD3 mAb (dilution: 1/100, UCHT1, BD Bioscience), APC-labeled
370 anti-CD4 mAb (dilution: 1/100, RPA-T4, Thermo Fisher Scientific), PE-labeled anti-CD19 mAb (HIB19, BioLegend),
371 Live/Dead (Thermo Fisher Scientific). Live-CD3⁺CD4⁺CD19⁻ cells were isolated using BD Biosciences FACS Aria II or
372 BD Biosciences FACS Aria III. CD4⁺ T cells and B cells were mixed in equal numbers in some samples.

373 The sorted cells were loaded to Chromium Next GEM Chip G (10x Genomics) on Chromium Controller (10x
374 Genomics) for barcoding and cDNA synthesis. The library construction was performed using Chromium Next GEM
375 Single Cell 5' Kit v2 and Chromium Single Cell Human TCR Amplification Kit (10x Genomics) for 5' according to the
376 manufacturer's protocol. The libraries were sequenced on NovaSeq6000 (Illumina).

377 **Preprocess of scRNA-seq data**

378 Sequenced reads were processed using Cell Ranger (v4.0.0) with pre-built reference refdata-gex-GRCh38-2020-A and
379 refdata-cellranger-vdj-GRCh38-alts-ensembl-4.0.0 downloaded at 10x GENOMICS' website. Quantified expressions
380 were preprocessed and visualized using Scanpy 1.8.1⁹⁷ and Python 3.8.0. For CD4⁺ T cell and B cell mixed samples, we
381 extracted only CD4⁺ T cells as following procedures. Briefly, we normalized (sc.pp.normalize_total) gene expression,
382 log-transformed it (sc.pp.log1p), extracted highly variable genes (HVGs) (sc.pp.highly_variable_genes with
383 min_mean=0.0125, max_mean=3, min_disp=0.5), computed PCA (sc.tl.pca) and neighbors (sc.pl.neighbors with
384 n_neighbors=10, n_pcs=40), computed clusters using Leiden algorithm (sc.tl.leiden), and embedded using UMAP
385 algorithm (sc.tl.umap). CD3E-positive and MS4A1-negative clusters were extracted as CD4⁺ T cells and used for the
386 analysis. Cells with mitochondrial genes were higher than 10%, detected genes less than 200, or annotated as multichain
387 by scirpy were filtered out. Variable genes of TCR alpha and beta were removed for the clustering and embedding to
388 remove the effect of clonal expansion. Gene expressions were preprocessed by sc.pp.normalize_per_cell with
389 counts_per_cell_after=1e4, sc.pp.log1pp, retained HVGs. The inference of the cell cycle was performed using the
390 sc.tl.score_genes_cell_cycle function following the tutorial
391 (https://nbviewer.jupyter.org/github/theislab/scanpy_usage/blob/master/180209_cell_cycle/cell_cycle.ipynb). Total
392 counts of UMI, % mitochondrial genes, S score, G2M score were regressed out using sc.tl.regress_out and scaled using
393 sc.tl.scale. Then, principal components were computed using sc.tl.pca. The batch effect of samples was removed by the
394 Harmony algorithm¹³. Cells were embedded by UMAP using sc.tl.umap (spread=1.5), and clustered using sc.tl.leiden
395 (resolution=1.2). Re-clustering and embedding were performed using sc.tl.umap (spread=1.5), clustered using sc.tl.leiden
396 (resolution=1.7) after removing clusters containing doublets with B cells, monocyte lineages, etc. We defined cluster L1
397 as a large classification using the leiden clusters. Next, for some clusters, concatenation or re-clustering was performed
398 with sc.tl.leiden (resolution 0.3-1) to divide clusters at the minimum resolution with distinct marker genes. We defined
399 cluster L2 as a smaller classification. Marker genes were determined using sc.tl.rank_genes_groups with method='t-
400 test_overestim_var'.

401 **Integration with bulk RNA-seq dataset**

402 Fastq files were processed using an RNA-seq integrative pipeline, ikra (v2.0.1)⁹⁸, composed of Trim Galore! 0.6.7⁹⁹,
403 Salmon 1.4.0¹⁰⁰, tximport 1.6.0¹⁰¹ with the reference Gencode M26 for mice and 37 for humans. Datasets for which the
404 TPM matrix was provided were downloaded and used directly for analyses. For the ImmuNexUT (E-GEAD-397) dataset,
405 the downloaded count matrix was converted to TPM.

406 For the correlations between bulk RNA-seq and scRNA-seq datasets, TPM or scaledTPM expression matrix of bulk
407 RNA-seq were normalized using sc.pp.normalize_per_cell (counts_per_cell_after=1e4), sc.pp.log1p, sc.pp.scale
408 (max_value=10), concatenated to scRNA-seq object, and calculated the correlations using sc.tl.dendrogram with the
409 default parameters.

410 **Gene expression decomposition using NMF**

411 To decompose cellular processes, we applied NMF implemented in scikit-learn (v0.24.2) to normalize gene expression
412 of HVGs. Using NMF, the normalized gene expression X was decomposed as follows;

413
$$X = W \cdot H$$

414 , where W and H possess n components. In the analysis, we set the number of components as 12 based on the two
415 criteria; i) more than the elbow in the distribution of explained variance, ii) before the jump up of the maximum inter-
416 components Spearman's correlation. The explained variance was calculated as follows;

417
$$RSS_c = \sum_{i,j} (x_{ij} - w_{ic}h_{ci})^2$$

418
$$Explained\ Variance = 1 - RSS_c / \sum_{i,j} x_{ij}^2$$

419 For the pathway enrichment analysis, we extracted the top 100 genes with the highest feature value for each component
420 and converted gene symbols into EntrezID using the bitr function provided by clusterProfiler (3.16.1)¹⁰² and computed
421 enriched Reactome pathways using the compareCluster function of clusterProfiler with the enrichPathway function in
422 ReactomePA (1.32.0). For the projection of gene features defined by NMF, we performed NMF with pre-computed W
423 using scikit-learn. The matrix W was converted to mouse genes using a list of human and mouse homologs provided at
424 <http://www.informatics.jax.org/homology.shtml>. For genes with multiple homologs, one of the genes was retained. For
425 the NMF calculation, only overlapped genes were used. To examine whether the selected HVGs of fixed W can capture
426 HVGs in a query dataset, we calculated the proportion of the number of HVGs included in fixed W against the number of
427 HVGs in the query dataset as POH. In the CD4⁺ T data set, we determined that if the POH is below 0.1, which is the
428 conservative threshold from the distribution of the null hypothesis (Figure S3C), there is a variance that cannot be
429 represented by the NMFproj. sc.pp.highly_variable_genes in scanpy with the following parameters; min_mean=0.0125,
430 max_mean=3, min_disp=0.1 was used for the calculation of HVGs of the query datasets and selected top 500 genes
431 regarding normalized dispersion¹⁰³ with the exclusion of VDJ genes of TCR and IG. A framework for NMF projection is
432 available at <https://github.com/yyoshiaki/NMFprojection>.

433 For the analysis of ImmuNexUT, the count data was downloaded at (<https://humandbs.biosciencedbc.jp/en/hum0214-v3>) and converted to TPM. We removed BD, AAV, AOSD, and SjS samples from the analysis because these samples are
434 processed in a different procedure from other samples. TPM matrix was decomposed with the pre-computed gene feature
435 matrix using NMFproj. Extracted NMF feature H was tested using a multiple linear regression provided as the
436 formula.api.ols function by a python package statsmodels (0.12.0) with a model, NMF_i ~ Disease + Age + Gender + 1.
437

438 **TCR analysis**

439 For TCR analysis, we used the standard pipeline of scirpy 0.10.1¹⁰⁴ according to the official tutorial
440 (https://scverse.org/scirpy/latest/tutorials/tutorial_3k_tcr.html). Briefly, clones were defined by clonotypes using
441 scirpy.tl.define_clonotypes with parameters; receptor_arms="all", dual_ir="primary_only". Repertoire similarities were
442 measured using the function scirpy.tl.repertoire_overlap. TiRP score was calculated according to the instruction in the
443 repository (<https://github.com/immunogenomics/TiRP.git>).

444 **Heritability partitioning**

445 To assess the contribution of each cell-type-specific gene expression and the NMF component, we applied S-LDSC
446 with Roadmap ABC-immune enhancer-gene linking strategy implemented using an sc-linker pipeline⁸⁵ with slight
447 modifications (<https://github.com/yyoshiaki/sclinker-skg>). We only used HVGs defined by the preprocessing section in
448 the analysis. We used min-max scaled gene scores for the cell-type gene programs as the gene weights. For NMF
449 components, we used the gene feature matrix W with the min-max scaling for the gene weights. Using the gene weights,
450 LD scores for each category were calculated with European LD scores used in the article⁸⁵ and Roadmap_U_ABC for
451 blood (https://storage.googleapis.com/broad-alkesgroup-public/LDSCORE/Dey_Enhancer_MasterReg/processed_data,
452 https://storage.googleapis.com/broad-alkesgroup-public/LDSCORE/DeepLearning/Dey_DeepBoost_Imperio/data_extra/AllPredictions.AvgHiC.ABC0.015.minus150.wt_hcolnames.ForABCPaper.txt.gz). In addition to the sumstats files provided in gs://broad-alkesgroup-public/LDSCORE/all_sumstats, we used several additional sumstats by processing using munge_sumstats.py in LDSC
455 v1.0.1 (Table S10). S-LDSC was performed with the baseline-LD model v2.1 (https://storage.googleapis.com/broad-alkesgroup-public/LDSCORE/1000G_Phase3_baselineLD_v2.1_ldscores.tgz). The Enrichment score (Escore) was
457 calculated as the difference between the enrichment for annotation in a particular program against an SNP annotation for
458 all protein-coding genes with a predicted enhancer-gene link in the blood. We also used FDR calculated from the p-value
459 of Enrichment outputted by S-LDSC.
460

461 **Meta-analysis of CD4⁺ T cells from public datasets**

462 We collected scRNA-seq data from PBMC generated by 10x platforms, Seq-Well or SPLiT-seq (Parse Biosciences WT
463 Mega)^{6,8,36-57} (Table S6). If the count matrix was available, we used the quantified matrix. Otherwise, we quantified the
464 expression using Cell Ranger with pre-built reference refdata-gex-GRCh38-2020-A. As the sample QC, samples with
465 XIST mean expression (count) > 0.05 were inferred as female. If the inferred gender and metadata differed, we removed
466 the sample from the analysis. We extracted CD4⁺ T cells from published data of PBMCs using Azimuth 0.4.4⁵⁸. We
467 created Seurat Object using the CreateSeuratObject function implemented in Seurat 4.1.0⁵⁸ with parameters min.cells=3,
468 min.features=200. We also filtered out the cells that express $\geq 10\%$ mitochondrial genes in their total gene expression. We
469 normalized the expression using SCTtransform with parameters method= "glmGamPoi", ncells=2000, n_genes=2000,
470 do.correct.umi=FALSE. In this procedure, we used Azimuth reference data v1.0.0 human_pbmc loaded from the website
471 (https://seurat.nogenome.org/azimuth/references/v1.0.0/human_pbmc). We found anchors between query data and
472 Azimuth reference data (FindTransferAnchors with parameters k.filter=NA, normalization.method= "SCT", dims=1:50,
473 n.trees=20, mapping.score.k=100), transferred cell type labels (TransferData with parameters dims=1:50, n.trees=20) and
474 calculated the embeddings on the reference supervised PCA (IntegrateEmbeddings with the default options) and
475 neighbors (FindNeighbors with parameter l2.norm=TRUE). We transformed an NN index (NNtransform with the
476 default parameters) and projected the query data to the reference UMAP (RunUMAP with the default parameters). We
477 visualized query data by DimPlot, DotPlot, and FeaturePlot.

478 Next, we mapped extracted cells on our reference using symphony 0.1.0¹⁴ following the vignettes
479 (<https://github.com/immunogenomics/symphony/blob/main/vignettes/Seurat.ipynb>). First, we created a symphony
480 reference using our dataset. Our scanpy object saved as an h5ad file was converted to h5Seurat using SeuratDisk and
481 loaded as a Seurat object. We used only HVGs for symphony reference to reduce batch effect strictly. Then, the object
482 was preprocessed as follows; SCTtransform (method= "glmGamPoi"), ScaleData, RunPCA, RunHarmony.Seurat
483 (group.by= "sample"), FindNeighbors (dims=1:30), RunUMAP2, and buildReferenceFromSeurat. For query mapping,
484 extracted CD4⁺ T cells were normalized (SCTtransform with parameter method= "glmGamPoi") and mapped (mapQuery
485 with parameter do_normalize=FALSE, vars = "batch") with batch correction against each sample. The cluster L1 and L2
486 assignments were performed using the knnPredict.Seurat function. We visualized the mapping results by DimPlot and
487 FeaturePlot as the quality control. We are providing the label transfer pipeline at
488 <https://github.com/yyoshiaki/screfmapping>.

489 Binomial regression was performed with the formula; $(n_cat, n_total - n_cat) \sim Disease + Age + Gender + Project$
490 using the R `glm` function. For the analysis of enriched NMF components, we first calculated cell profiles using `NMFproj`
491 with raw counts, and linear regression was performed with the formula; $NMF_i \sim Disease + Age + Gender + Project$
492 using the R `glm` function. For the PCA plot of individuals, we corrected the batch effect by a project by regressing out
493 using `GLM` with the formula; $cell\ frequency \sim Disease + Age + Gender + Project$. The Chord diagrams were created
494 using `pycircosize` (0.1.3).

495 **Machine learning for the prediction of autoimmune states**

496 First, the training and test datasets were split without the study overlap. Cell frequencies and/or `NMFproj` values in `Tcm`
497 (`Th0`) and `Tnaive` were scaled using `StandardScaler` (`scikit-learn` 1.0.2). Note that `Tnaive` and `Tcm(Th0)`, which have a
498 high degree of nodes in the network, were selected for the `NMFproj` results to keep the number of parameters low. `NMF`
499 values were imputed using `SimpleImputer` (`scikit-learn` 1.0.2) with parameter `strategy='most_frequent'` trained by training
500 datasets. For the binary classification, we used the `LogisticRegression` in `scikit-learn` with the default parameters. For the
501 multiclass classification, the label imbalance was corrected using `SMOTE` (`imbalanced-learn` 0.9.1) with parameter
502 `sampling_strategy='all'`. Then, `LightGBM` 3.3.2¹⁰⁵ was used for the model with parameters, `'objective='multiclass'` and
503 `'early_stopping_rounds'=10`.

504 **Statistical analyses**

505 All statistical analyses were performed in R (4.0.3 or 4.1.2) and Python (3.8.0). FDR was obtained by the Benjamini-
506 Hochberg procedure implemented by a Python package `statsmodels` (0.12.0). All other statistical analyses are detailed in
507 the respective sections of the article.

508 **Acknowledgments**

509 This work was supported by Grant-in-Aid for Specially Promoted Research Grant 16H06295 from the Ministry of
510 Education, Culture, Sports, Science, and Technology of Japan and Leading Advanced Projects for Medical Innovation
511 (LEAP, no. 18 gm0010005h0001) from Japan's Agency for Medical Research and Development (AMED) to S.S. Y.Y.
512 was supported by Takeda Science Foundation. D.T. was supported by the Osaka University Medical Doctor Scientist
513 Training Program. We acknowledge the NGS core facility of the Genome Information Research Center at the Research
514 Institute for Microbial Diseases of Osaka University for its support in RNA sequencing. This work was partly achieved
515 through the use of SQUID at the Cybermedia Center, Osaka University. Some illustrations were generated with
516 BioRender.com. The authors wish to acknowledge Dr. Hirotaka Matsumoto, Nagasaki University for his constructive

517 feedback on NMFproj, Dr. Kazuyoshi Ishigaki, RIKEN for technical advice for TiRP analysis, Nicole Carter and Sarah
518 Schroeder, Parse Biosciences, Dr. Francesca Capon and Dr. Daniel McCluskey, King's College London, Dr. Karine
519 Chemin, Karolinska institutet, Dr. Lennart M. Roesner, Hannover Medical School (MHH) for sharing single-cell RNA-
520 seq data, and Dr. James Wing for critical comments on the manuscript.

521 **Data and materials availability**

522 Data sets will be available upon publication. NMFproj is provided at
523 <https://github.com/yyoshiaki/NMFprojection>. Detailed results of the meta-analysis and sclinker were deposited at
524 https://yyoshiaki.github.io/autoimmune_scRNAseq/Tcells.html.

525 **Author contributions**

526 Y.Y., D.T., R.M., N.O., and S.S. designed all experiments; Y.N. performed experiments under the supervision of N.O;
527 Y.Y., D.T., and R.M. performed bioinformatics analysis; Y.Y., T.O., M.K., T.M., Y.K., A.K., and H.M. collected
528 samples for analysis; M. W. and X. Z. provided single-cell RNA-seq data; D.M. and D.O. performed library construction
529 and sequencing; Y.T., N.M., and M.A. provided expert advice; Y.Y. prepared the figures; Y.Y., D.T., and R.M. drafted
530 the manuscript; N.O. and S.S. supervised the study; All authors critically reviewed and edited the final version of the
531 manuscript.

532 **Declaration of interests**

533 The authors declare no competing interests.

534 **Figure titles and legends**

535 **Figure 1 Global profiling of CD4⁺ T cells**

536 (A) Sample collection strategy.

537 (B and C) Clusters L1 and L2 on UMAP embeddings.

538 (D) Dot plot depicting signature genes' mean expression levels and percentage of cells expressing them across clusters.

539 Marker genes for the plot were manually selected. See also Figure S1C for automatically extracted marker genes.

540 (E) Expression correlation of clusters with bulk RNA-seq for sorted CD4⁺ T cell fractions (DICE).

541 (F) UMAP plot showing clonotype size.

542 (G and H) Clonotype size distributions across clusters.

543 (I and J) TCR similarity networks in autoimmune patients, healthy donors (I), and all donors (J). TCR similarity was
544 calculated for each sample, and only edges where overlapping clonotypes were detected in $>=2$ (I) or $>=4$ (J) samples are
545 depicted as robust overlaps. The edge color indicates the average TCR similarity of all samples.
546 (K) Degree centrality of TCR networks. Significance across clusters was calculated by one-way ANOVA, and after
547 multiple test corrections by FDR, Tcm (Tfh) and Treg Act were retained as significant cell types. Then, pairwise Tukey-
548 HSD posthoc tests were performed. *: $p_{adj} < 0.05$ in comparison with HC.
549 (L) TiRP score distributions on UMAP plot. Mean scores for each cluster L2 were shown.
550 (M) TiRP score distribution across cluster L2. The dot shows the mean, and the CI shows 95% CI of the bootstrap
551 distribution of means (n=1000). Adjusted p-values of significant clusters, Tnaive MXI 1.29×10^{-2} , Tem (Th1) 5.82×10^{-11} ,
552 Temra (Th1) 4.84×10^{-22} , Treg Naive 2.14×10^{-13} , Treg Act 2.14×10^{-13} , Treg Eff 3.82×10^{-5} (Two-sided Mann-Whitney's
553 U-test was performed for one cluster vs. the other clusters iteratively).

554 **Figure 2 NMF captured 12 CD4⁺ T cell features**

555 (A) Schematic view of NMF and NMF projection.
556 (B) Matrixplot showing the mean scaled NMF feature weight for each cluster L2 population. The explained variance
557 (Evar) is also shown on the right. The NMF feature weight is scaled by the maximum value for each feature for
558 visualization.
559 (C) NMF cell feature value on UMAP plots.
560 (D) Gene features for each component. The top 10 genes for each feature were selected.
561 The 12 gene features are annotated using top genes and previous reports as NMF0 Cytotoxic-Feature (F), NMF1 Treg-F,
562 NMF2 Th17-F, NMF3 Naive-F, NMF4 Activation-F (Act-F), NMF5 TregEff/Th2-F, NMF6 Tfh-F, NMF7 IFN-F, NMF8
563 Central Memory-F, NMF9 Thymic emigrant-F, NMF10 Tissue-F, NMF11 Th1-F.

564 **Figure 3 Pan-autoimmune meta-analysis of peripheral CD4⁺ T cells**

565 (A) Strategy for meta-analysis of peripheral CD4⁺ T cells across diseases. First, CD4⁺ T cells were extracted from PBMC
566 scRNA-seq datasets using Azimuth⁵⁸. Extracted CD4⁺ T cells were mapped on our reference using Symphony¹⁴ with a
567 batch correction. Mapped cells were used to assess cell frequency and NMF cell features for each cluster.
568 (B) Bar plots showing the number of samples (left) and the number of CD4⁺ T cells (right) enrolled in the meta-analysis.
569 The dashed line in the left plot indicates a sample size of 10.

570 (C) Dot plot showing changes in cell frequency at cluster L2 resolution. Dot colors show coefficients, and sizes show the
571 significance of the Generalized Linear Model (Methods). Detailed statistics can be found in Table S8. Only significant
572 dots ($p_{adj} < 0.05$) are shown.

573 (D-F) PCA plots of samples based on cell frequencies. Sample distributions for each disease state (D), loading vectors for
574 each cell type (E), and sample characteristics in healthy donors (F) are shown.

575 (G) Chord diagram showing the top 100 significant associations with positive coefficients between NMF features and
576 cells in each condition, calculated by GLM (Methods). Detailed statistics are shown in Table S9. The thickness of edges
577 indicates the coefficient of GLM, and colors indicate conditions such as diseases, gender, and age.

578 (H) Strategy for predicting autoimmune states from CD4⁺ T cell profiles using machine learning framework. As the input
579 parameters, one model took only cell frequency, age, and gender (without NMFproj), while the other took cell frequency,
580 NMF cell features in Tcm (Th0) and Tnaive, age, and gender (with NMFproj).

581 (I) Receiver operating characteristic (ROC) curves of logistic regression models trained by cell frequencies (top left), by
582 NMFproj values in Tnaive and Tcm (Th0) (top right), and both cell frequencies and NMFproj values (bottom). SLE,
583 COVID-19, and SLE patients were trained on 159, 116, and 35 patients with the same number of healthy subjects, and
584 evaluated on 40, 89, and 17 patients and the same number of healthy subjects from independent data sets. Numbers in
585 parentheses indicate the area under the curve (AUC).

586 **Figure 4 Partitioned heritability of autoimmune diseases by CD4⁺ T cell features**

587 (A) Bar plot showing maximum $-\log_{10}(q\text{-}Escore)$ among NMF gene features. Partitioned heritability was measured using
588 the sclinker framework. Enrichment of each category is the following, Autoimmune diseases: $p=8.51 \times 10^{-12}$,
589 inflammatory traits: $p=0.131$, and blood cell count: $p=7.59 \times 10^{-8}$ (Two-sided Mann-Whitney's U-test).

590 (B) Dot plot showing enrichment of partitioned heritability of autoimmune diseases across NMF gene features. The
591 dashed boxes indicate the factor with the highest Escore for each disease. Duplicated traits were removed for the
592 visualization. Full statistics are shown in Table S11.

593 **Figure 5 Relationship between genetic factors and phenotypic changes in CD4⁺ T cells**

594 (A) Model of genetic effect on phenotypic changes in CD4⁺ T cells. CD4⁺ T cell changes are observed as qualitative
595 (NMFproj cell features) and quantitative (cell-type frequencies) changes.

596 (B) Scatter plot showing the genetic effect on cell frequencies (x-axis) and NMF features (y-axis). Sclinker weight per
597 cell was calculated by dot products of sclinker outcome (NMF) and NMF cell features. For cell frequencies and NMF
598 cell features, coefficients of GLM output for each cluster L2 population were used. Spearman's correlation of sclinker

599 weight and cell frequency / NMF cell feature changes were calculated. For the correlation with sclinker and NMF cell
600 feature changes, we used the maximum R among NMF features for the visualization. COVID19-A : Very severe
601 respiratory symptom, COVID19-B : Hospitalized, COVID19-C: SARS-CoV-2 infection.
602 (C) Individual sclinker weights, cell frequency changes (Coef. for each cluster L2), and NMF cell feature changes in the
603 factor with the highest Escore (Coef. for each cluster L2) of MS, MG, and SLE were visualized on the UMAP
604 embeddings (left panel). For the coefficient of the NMF cell feature changes, only one representative factor with the
605 highest Escore for each disease was shown. The bar plot of Spearman's correlation of cell frequency and NMFproj
606 changes with partitioned heritability is shown in the right panel. The colors of the bars except for cell frequency, indicate
607 Escores calculated using sclinker.
608

609 **Supplementary Figure Legends**

610 **Figure S1. Global characterization of CD4⁺ T cells**

611 (A) UMAP plots depicting gene expressions of marker genes.

612 (B) Sankey diagrams showing cluster assignment of cells in clusters L1 and L2.

613 (C) Dot plot depicting signature genes' mean expression levels and percentage of cells expressing them across clusters.

614 Marker genes for the plot were calculated by pairwise comparison with a group and the other groups iteratively using
615 `scipy.tl.rank_genes_groups` function.

616 (D) Density plot of cell distributions for cluster L2 populations.

617 (E) Dot plot depicting Tph and Tfh marker genes' mean expression levels and percentage of cells expressing them in Tcm
618 (Tfh) and Tem (Tph).

619 (F) Pearson's correlation of transcriptome profiles between sorted T cell fractions, including Tph (SDY939) and our
620 scRNA-seq (cluster L2).

621 (G) Density plot of cell distributions for each disease.

622 **Figure S2. Centralities of TCR networks vary depending on the diseases**

623 (A) Degree centrality of TCR networks for cluster L2. The average of each disease was shown.

624 (B) Individual value of degree centrality of TCR networks.

625 (C) Distribution of mean TiRP scores across Treg clusters. Pairwise Tukey-HSD posthoc tests. The multiple test
626 correction was performed using a two-stage FDR strategy. *: $p_{adj} < 0.05$, **: $p_{adj} < 0.01$, ***: $p_{adj} < 0.001$.

627 (D) Changes in TiRP scores in Treg clusters associated with disease states, age, and sex. The estimated coefficients and
628 the 95 percentiles by multiple linear regression were plotted.

629 **Figure S3. NMF and NMF projection**

630 (A) The statistics for the determination of the number of components. The Y-axis shows explained variance (upper) and
631 maximum correlation of the inter-component (lower). The X-axis shows the number of components. Spearman's
632 correlation between components of gene features was calculated.

633 (B) Reactome pathways enriched in each gene feature. The dot size indicates the gene ratio or the fraction of genes found
634 in the gene set, and the color indicates p_{adj} .

635 (C) Histogram of POH under the null hypothesis for this study setting. We randomly sampled 5000 POH in the null
636 hypothesis calculated from the overlap between random 500 (number of HVGs for the calculation of POH) genes and
637 1271 (number of HVGs of CD4⁺ T cell) genes. Red dashed lines show 2.5 and 97.5 percentiles.
638 (D) Heatmap showing NMF values of DICE bulk RNA-seq datasets of sorted CD4⁺ T cell fractions. Explained variance
639 (Evar) was also shown on the right side.
640 (E) Heatmap showing NMF values of sorted CD4⁺ T cell fractions by Miyara's classification (JGAD000214). Explained
641 variance (Evar) was also shown on the right side.
642 (F) Heatmap showing NMF values of sorted Tph fractions (SDY939). Explained variance (Evar) was also shown on the
643 right side.
644 (G) Heatmap showing NMF values of iTreg cells cultured in different conditions (DRA008294). Explained variance
645 (Evar) was also shown on the right side.

646 **Figure S4. NMFproj applications in tumor-infiltrating T cells and mouse splenocytes**
647 (A and B) UMAP plots showing original cell types (left) and projected NMF cell feature values (right) in pan-cancer
648 tumor-infiltrating T cells scRNA-seq data (GSE156728) (A) and mouse splenic CD4⁺ T cells (SCP490) (B).

649 **Figure S5. NMFproj contributes to interpreting cross-tissue T cells**
650 (A) Projected NMF cell feature value of cross-tissue T cells scRNA-seq datasets on the UMAP plots. The T & innate
651 lymphoid cells dataset was used for the analysis (<https://www.tissueimmunecellatlas.org/>).
652 (B and C) Original cell types (B) and the expression of CD4 and CD8A (C) were shown on the UMAP plots.
653 (D and E) Distribution of POH (D) and Evar (E) in each tissue. THY: Thymus, BLD: Blood, BMA: Bone marrow, MLN:
654 Mesenchymal lymph nodes, LLN: Lung-draining lymph nodes, SPL: Spleen, SKM: Skeletal muscle, LNG: Lung, LIV:
655 Liver, OME: Omentum, TCL: Transverse colon, SCL: Sigmoid colon, DUO: Duodenum, CAE: Caecum, ILE: Ileum,
656 JEJLP: Jejunum lamina propria, JEJEPI: Jejunum epithelial. The dashed line indicates the 97.5 percentile of simulated
657 null distribution (Fig. S3C).
658 (F and G) Distribution of POH (F) and Evar (G) in each cell type. B and Myeloid cells were also added to the analysis.
659 The dashed line indicates the 97.5 percentile of simulated null distribution (Fig. S3C).

660 **Figure S6. NMFproj reveals disease-specific qualitative changes**
661 (A) Heatmap showing NMF values of sorted CD4⁺ T cell fractions collected from autoimmune patients (E-GEAD-397).
662 Explained variance (Evar) was also shown on the right side.

663 (B) Dot plot depicting NMF cell feature changes in each cell type in E-GEAD-397. Dot colors show coefficients, and
664 sizes show the significance of GLM. GLM was performed with a model, cell frequency, or NMF cell feature ~ disease +
665 age + gender. IIM: idiopathic inflammatory myopathy, MCTD: mixed connective tissue disease, RA: rheumatoid arthritis,
666 SLE: systemic lupus erythematosus, SSc: systemic sclerosis, TAK: Takayasu arteritis.

667 **Figure S7. Quantitative alterations revealed by meta-analysis**

668 (A) Swarm plot showing frequencies of cell types in each sample.
669 (B) Dot plot showing changes in cell frequency at cluster L1 resolution. Dot colors show coefficients, and sizes show the
670 significance of the Generalized Linear Model (Methods). Detailed statistics can be found in Table S7. Only significant
671 dots ($p_{adj} < 0.05$) are shown.
672 (C) Cell frequencies of each population are shown on the PCA plots.
673 (D) Distribution of samples for each disease.

674 **Figure S8. Alterations in CD4⁺ T cells revealed by meta-analysis**

675 (A) Chord diagram showing the top 100 significant associations with negative coefficients between NMF features and
676 cells in each condition, calculated by GLM (Methods). Detailed statistics are shown in Table S9. The thickness of edges
677 indicates the absolute value of the coefficient of GLM, and colors indicate conditions such as diseases, gender, and age.
678 (B) Strategy for multiclass classification by machine learning. The training was performed with cross-validation. The
679 evaluation was performed using the independent dataset of training datasets.
680 (C) Evaluations of models trained by cell frequencies (upper panel), by NMFproj values in Tnaive and Tcm (Th0)
681 (middle panel), and by both cell frequencies and NMFproj values (lower panel). The confusion matrix (left) and PR-
682 AUC (right) are shown. The dashed lines in the PR-AUC plot show the expected PR-AUC scores in random models. The
683 number of samples used for the training is 263, 27, 62, 11, 43, 20, 156, 116, 11 subjects for HC, sarcoidosis, psoriasis,
684 celiac disease, MS, RA, SLE, COVID-19, and T1D, and evaluated on 89, 43, 43, and 9 subjects from independent data
685 sets.

686 **Figure S9. NMF cell feature changes depending on diseases**

687 Dot plots depicting NMF cell feature changes in each cell type. Dot colors show coefficients, and sizes show the
688 significance of GLM. GLM was performed with a model, NMF cell feature ~ disease + age + gender + project. Only
689 significant dots ($p_{adj} < 0.05$) are shown.

690 **Figure S10. Partitioned heritability**

691 (A and B) Dot plots showing partitioned heritability of diseases across NMF gene features (A) or cell types
692 (B). Duplicated traits were removed for the visualization. Full statistics are shown in Tables S11 and 12.

693 **Reference**

- 694 1. Farh, K.K.-H., Marson, A., Zhu, J., Kleinewietfeld, M., Housley, W.J., Beik, S., Shoresh, N., Whitton, H., Ryan, R.J.H., Shishkin, A.A., et al. (2015). Genetic and epigenetic fine mapping of causal autoimmune disease variants. *Nature* *518*, 337–343.
- 695 2. Ohkura, N., Yasumizu, Y., Kitagawa, Y., Tanaka, A., Nakamura, Y., Motooka, D., Nakamura, S., Okada, Y., and Sakaguchi, S. (2020). Regulatory T Cell-Specific Epigenomic Region Variants Are a Key Determinant of Susceptibility to Common Autoimmune Diseases. *Immunity* *52*, 1119–1132.e4.
- 696 3. Wang, L., Wang, F.-S., and Gershwin, M.E. (2015). Human autoimmune diseases: a comprehensive update. *J. Intern. Med.* *278*, 369–395.
- 697 4. Zhu, J., Yamane, H., and Paul, W.E. (2010). Differentiation of effector CD4 T cell populations (*). *Annu. Rev. Immunol.* *28*, 445–489.
- 698 5. Sakaguchi, S., Mikami, N., Wing, J.B., Tanaka, A., Ichiyama, K., and Ohkura, N. (2020). Regulatory T Cells and Human Disease. *Annu. Rev. Immunol.* *38*, annurev-immunol-042718-041717.
- 699 6. Perez, R.K., Gordon, M.G., Subramaniam, M., Kim, M.C., Hartoularos, G.C., Targ, S., Sun, Y., Ogorodnikov, A., Bueno, R., Lu, A., et al. (2022). Single-cell RNA-seq reveals cell type–specific molecular and genetic associations to lupus. *Science* *376*. 10.1126/science.abf1970.
- 700 7. Yasumizu, Y., Ohkura, N., Murata, H., Kinoshita, M., Funaki, S., Nojima, S., Kido, K., Kohara, M., Motooka, D., Okuzaki, D., et al. (2022). Myasthenia gravis-specific aberrant neuromuscular gene expression by medullary thymic epithelial cells in thymoma. *Nat. Commun.* *13*, 4230.
- 701 8. Schafflick, D., Xu, C.A., Hartlehner, M., Cole, M., Schulte-Mecklenbeck, A., Lautwein, T., Wolbert, J., Heming, M., Meuth, S.G., Kuhlmann, T., et al. (2020). Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis. *Nat. Commun.* *11*. 10.1038/s41467-019-14118-w.
- 702 9. Zhang, F., Wei, K., Slowikowski, K., Fonseka, C.Y., Rao, D.A., Kelly, S., Goodman, S.M., Tabachian, D., Hughes, L.B., Salomon-Escoto, K., et al. (2019). Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry. *Nat. Immunol.* *20*, 928–942.
- 703 10. Martin, J.C., Chang, C., Boschetti, G., Merad, M., Cho, J.H., and Correspondence, E.K. (2019). Single-Cell Analysis of Crohn’s Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy. *Cell* *178*, 1–16.
- 704 11. Argyriou, A., Wadsworth, M.H., 2nd, Lendvai, A., Christensen, S.M., Henvold, A.H., Gerstner, C., van Vollenhoven, A., Kravarik, K., Winkler, A., Malmström, V., et al. (2022). Single cell sequencing identifies clonally expanded synovial CD4+ TPH cells expressing GPR56 in rheumatoid arthritis. *Nat. Commun.* *13*, 4046.
- 705 12. Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalex, E., Mauck, W.M., Hao, Y., Stoeckius, M., Smibert, P., and Satija, R. (2019). Comprehensive Integration of Single-Cell Data. *Cell* *177*, 1888–1902.e21.
- 706 13. Korsunsky, I., Millard, N., Fan, J., Slowikowski, K., Zhang, F., Wei, K., Baglaenko, Y., Brenner, M., Loh, P. ru, and Raychaudhuri, S. (2019). Fast, sensitive and accurate integration of single-cell data with Harmony. *Nat. Methods* *16*, 1289–1296.
- 707 14. Kang, J.B., Nathan, A., Weinand, K., Zhang, F., Millard, N., Rumker, L., Moody, D.B., Korsunsky, I., and Raychaudhuri, S. (2021). Efficient and precise single-cell reference atlas mapping with Symphony. *Nat. Commun.* *12*, 5890.

732 15. Zheng, L., Qin, S., Si, W., Wang, A., Xing, B., Gao, R., Ren, X., Wang, L., Wu, X., Zhang, J., et al. (2021). Pan-
733 cancer single-cell landscape of tumor-infiltrating T cells. *Science* *374*, 10.1126/science.abe6474.

734 16. Nathan, A., Asgari, S., Ishigaki, K., Valencia, C., Amariuta, T., Luo, Y., Beynor, J.I., Baglaenko, Y., Suliman, S.,
735 Price, A.L., et al. (2022). Single-cell eQTL models reveal dynamic T cell state dependence of disease loci. *Nature*
736 *606*, 120–128.

737 17. Morabito, S., Miyoshi, E., Michael, N., Shahin, S., Martini, A.C., Head, E., Silva, J., Leavy, K., Perez-Rosendahl,
738 M., and Swarup, V. (2021). Single-nucleus chromatin accessibility and transcriptomic characterization of
739 Alzheimer's disease. *Nat. Genet.* *53*, 1143–1155.

740 18. Stein-O'Brien, G.L., Arora, R., Culhane, A.C., Favorov, A.V., Garmire, L.X., Greene, C.S., Goff, L.A., Li, Y., Ngom,
741 A., Ochs, M.F., et al. (2018). Enter the Matrix: Factorization Uncovers Knowledge from Omics. *Trends Genet.* *34*,
742 790–805.

743 19. Schmiedel, B.J., Singh, D., Madrigal, A., Valdovino-Gonzalez, A.G., White, B.M., Zapardiel-Gonzalo, J., Ha, B.,
744 Altay, G., Greenbaum, J.A., McVicker, G., et al. (2018). Impact of Genetic Polymorphisms on Human Immune Cell
745 Gene Expression. *Cell* *175*, 1701–1715.e16.

746 20. Rao, D.A., Gurish, M.F., Marshall, J.L., Slowikowski, K., Fonseka, C.Y., Liu, Y., Donlin, L.T., Henderson, L.A.,
747 Wei, K., Mizoguchi, F., et al. (2017). Pathologically expanded peripheral T helper cell subset drives B cells in
748 rheumatoid arthritis. *Nature* *542*, 110–114.

749 21. Yoshitomi, H., and Ueno, H. (2021). Shared and distinct roles of T peripheral helper and T follicular helper cells in
750 human diseases. *Cell. Mol. Immunol.* *18*, 523–527.

751 22. Asashima, H., Mohanty, S., Comi, M., Ruff, W.E., Hoehn, K.B., Wong, P., Klein, J., Lucas, C., Cohen, I., Coffey, S.,
752 et al. (2023). PD-1highCXCR5-CD4+ peripheral helper T cells promote CXCR3+ plasmablasts in human acute
753 viral infection. *Cell Rep.* *42*, 111895.

754 23. Ohkura, N., Hamaguchi, M., Morikawa, H., Sugimura, K., Tanaka, A., Ito, Y., Osaki, M., Tanaka, Y., Yamashita, R.,
755 Nakano, N., et al. (2012). T Cell Receptor Stimulation-Induced Epigenetic Changes and Foxp3 Expression Are
756 Independent and Complementary Events Required for Treg Cell Development. *Immunity* *37*, 785–799.

757 24. Lagattuta, K.A., Kang, J.B., Nathan, A., Pauken, K.E., Jonsson, A.H., Rao, D.A., Sharpe, A.H., Ishigaki, K., and
758 Raychaudhuri, S. (2022). Repertoire analyses reveal T cell antigen receptor sequence features that influence T cell
759 fate. *Nat. Immunol.* *23*, 446–457.

760 25. Rosenblum, M.D., Way, S.S., and Abbas, A.K. (2016). Regulatory T cell memory. *Nat. Rev. Immunol.* *16*, 90–101.

761 26. Delacher, M., Imbusch, C.D., Hotz-Wagenblatt, A., Mallm, J.-P., Bauer, K., Simon, M., Riegel, D., Rendeiro, A.F.,
762 Bittner, S., Sanderink, L., et al. (2020). Precursors for nonlymphoid-tissue Treg cells reside in secondary lymphoid
763 organs and are programmed by the transcription factor BATF. *Immunity* *52*, 295–312.e11.

764 27. Wing, J.B., Kitagawa, Y., Locci, M., Hume, H., Tay, C., Morita, T., Kidani, Y., Matsuda, K., Inoue, T., Kurosaki, T.,
765 et al. (2017). A distinct subpopulation of CD25⁺ T-follicular regulatory cells localizes in the germinal centers.
766 *Proceedings of the National Academy of Sciences* *114*, E6400–E6409.

767 28. Gate, D., Tapp, E., Leventhal, O., Shahid, M., Nonninger, T.J., Yang, A.C., Strempfl, K., Unger, M.S., Fehlmann, T.,
768 Oh, H., et al. (2021). CD4⁺ T cells contribute to neurodegeneration in Lewy body dementia. *Science* *7266*, 1–11.

769 29. Boyman, O., Purton, J.F., Surh, C.D., and Sprent, J. (2007). Cytokines and T-cell homeostasis. *Curr. Opin. Immunol.*
770 *19*, 320–326.

771 30. Miyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., Parizot, C., Taflin, C., Heike, T., Valeyre, D., et
772 al. (2009). Functional Delineation and Differentiation Dynamics of Human CD4⁺ T Cells Expressing the FoxP3
773 Transcription Factor. *Immunity* *30*, 899–911.

774 31. Mikami, N., Kawakami, R., Chen, K.Y., Sugimoto, A., Ohkura, N., and Sakaguchi, S. (2020). Epigenetic conversion
775 of conventional T cells into regulatory T cells by CD28 signal deprivation. *Proc. Natl. Acad. Sci. U. S. A.* *117*,
776 12258–12268.

777 32. Domínguez Conde, C., Xu, C., Jarvis, L.B., Rainbow, D.B., Wells, S.B., Gomes, T., Howlett, S.K., Suchanek, O.,
778 Polanski, K., King, H.W., et al. (2022). Cross-tissue immune cell analysis reveals tissue-specific features in humans.
779 *Science* **376**. 10.1126/science.abl5197.

780 33. Elyahu, Y., Hekselman, I., Eizenberg-Magar, I., Berner, O., Strominger, I., Schiller, M., Mittal, K., Nemirovsky, A.,
781 Eremenko, E., Vital, A., et al. (2019). Aging promotes reorganization of the CD4 T cell landscape toward extreme
782 regulatory and effector phenotypes. *Science Advances* **5**. 10.1126/sciadv.aaw8330.

783 34. Valencia, X., Yarboro, C., Illei, G., and Lipsky, P.E. (2007). Deficient CD4+CD25high T regulatory cell function in
784 patients with active systemic lupus erythematosus. *J. Immunol.* **178**, 2579–2588.

785 35. Ota, M., Nagafuchi, Y., Hatano, H., Ishigaki, K., Terao, C., Takeshima, Y., Yanaoka, H., Kobayashi, S., Okubo, M.,
786 Shirai, H., et al. (2021). Dynamic landscape of immune cell-specific gene regulation in immune-mediated diseases.
787 *Cell* **184**, 3006-3021.e17.

788 36. Nehar-Belaid, D., Hong, S., Marches, R., Chen, G., Bolisetty, M., Baisch, J., Walters, L., Punaro, M., Rossi, R.J.,
789 Chung, C.H., et al. (2020). Mapping systemic lupus erythematosus heterogeneity at the single-cell level. *Nat.*
790 *Immunol.* **21**, 1094–1106.

791 37. Garman, L., Pelikan, R.C., Rasmussen, A., Lareau, C.A., Savoy, K.A., Deshmukh, U.S., Bagavant, H., Levin, A.M.,
792 Daouk, S., Drake, W.P., et al. (2020). Single Cell Transcriptomics Implicate Novel Monocyte and T Cell Immune
793 Dysregulation in Sarcoidosis. *Front. Immunol.* **11**, 567342.

794 38. Stephenson, E., Reynolds, G., Botting, R.A., Calero-Nieto, F.J., Morgan, M.D., Tuong, Z.K., Bach, K., Sungnak, W.,
795 Worlock, K.B., Yoshida, M., et al. (2021). Single-cell multi-omics analysis of the immune response in COVID-19.
796 *Nat. Med.* **27**, 904–916.

797 39. Wang, Z., Xie, L., Ding, G., Song, S., Chen, L., Li, G., Xia, M., Han, D., Zheng, Y., Liu, J., et al. (2021). Single-cell
798 RNA sequencing of peripheral blood mononuclear cells from acute Kawasaki disease patients. *Nat. Commun.* **12**,
799 5444.

800 40. Lefferts, A.R., Regner, E.H., Stahly, A., O'Rourke, B., Gerich, M.E., Fennimore, B.P., Scott, F.I., Freeman, A.E.,
801 Jones, K., and Kuhn, K.A. (2021). Circulating mature granzyme B+ T cells distinguish Crohn's disease-associated
802 axial spondyloarthritis from axial spondyloarthritis and Crohn's disease. *Arthritis Res. Ther.* **23**, 147.

803 41. Liu, J., Kumar, S., Hong, J., Huang, Z.-M., Paez, D., Castillo, M., Calvo, M., Chang, H.-W., Cummins, D.D., Chung,
804 M., et al. (2022). Combined Single Cell Transcriptome and Surface Epitope Profiling Identifies Potential
805 Biomarkers of Psoriatic Arthritis and Facilitates Diagnosis via Machine Learning. *Front. Immunol.* **13**, 835760.

806 42. Ramírez-Sánchez, A.D., Chu, X., Modderman, R., Kooy-Winkelhaar, Y., Koletzko, S., Korponay-Szabó, I.R.,
807 Troncone, R., Wijmenga, C., Mearin, L., Withoff, S., et al. (2022). Single-Cell RNA Sequencing of Peripheral
808 Blood Mononuclear Cells From Pediatric Coeliac Disease Patients Suggests Potential Pre-Seroconversion Markers.
809 *Front. Immunol.* **13**, 843086.

810 43. Paley, M.A., Baker, B.J., Dunham, S.R., Linskey, N., Cantoni, C., Lee, K., Hassman, L.M., Laurent, J., Roberson,
811 E.D.O., Clifford, D.B., et al. (2022). The CSF in neurosarcoidosis contains consistent clonal expansion of CD8 T
812 cells, but not CD4 T cells. *J. Neuroimmunol.* **367**, 577860.

813 44. Kaufmann, M., Evans, H., Schaupp, A.-L., Broder Engler, J., Kaur, G., Willing, A., Kursawe, N., Schubert, C.,
814 Attfield, K.E., Fugger, L., et al. (2021). Identifying CNS-colonizing T cells as potential therapeutic targets to
815 prevent progression of multiple sclerosis. *Med*, 1–17.

816 45. Cai, Y., Dai, Y., Wang, Y., Yang, Q., Guo, J., Wei, C., Chen, W., Huang, H., Zhu, J., Zhang, C., et al. (2020). Single-
817 cell transcriptomics of blood reveals a natural killer cell subset depletion in tuberculosis. *EBioMedicine* **53**, 102686.

818 46. Wu, X., Liu, Y., Jin, S., Wang, M., Jiao, Y., Yang, B., Lu, X., Ji, X., Fei, Y., Yang, H., et al. (2021). Single-cell
819 sequencing of immune cells from anticitrullinated peptide antibody positive and negative rheumatoid arthritis. *Nat.*
820 *Commun.* **12**, 4977.

821 47. Hong, X., Meng, S., Tang, D., Wang, T., Ding, L., Yu, H., Li, H., Liu, D., Dai, Y., and Yang, M. (2020). Single-Cell
822 RNA Sequencing Reveals the Expansion of Cytotoxic CD4+ T Lymphocytes and a Landscape of Immune Cells in
823 Primary Sjögren's Syndrome. *Front. Immunol.* **11**, 594658.

824 48. Lee, J.S., Park, S., Jeong, H.W., Ahn, J.Y., Choi, S.J., Lee, H., Choi, B., Nam, S.K., Sa, M., Kwon, J.S., et al. (2020).
825 Immunophenotyping of covid-19 and influenza highlights the role of type i interferons in development of severe
826 covid-19. *Science Immunology* 5, 1–14.

827 49. Wilk, A.J., Rustagi, A., Zhao, N.Q., Roque, J., Martínez-Colón, G.J., McKechnie, J.L., Ivison, G.T., Ranganath, T.,
828 Vergara, R., Hollis, T., et al. (2020). A single-cell atlas of the peripheral immune response in patients with severe
829 COVID-19. *Nat. Med.* 26, 1070–1076.

830 50. McCluskey, D., Benzian-Olsson, N., Mahil, S.K., Hassi, N.K., Wohlnhaas, C.T., APRICOT and PLUM study team,
831 Burden, A.D., Griffiths, C.E.M., Ingram, J.R., Levell, N.J., et al. (2022). Single-cell analysis implicates T_H17 -to-
832 T_H2 cell plasticity in the pathogenesis of palmoplantar pustulosis. *J. Allergy Clin. Immunol.*
833 10.1016/j.jaci.2022.04.027.

834 51. Ren, X., Wen, W., Fan, X., Hou, W., Su, B., Cai, P., Li, J., Liu, Y., Tang, F., Zhang, F., et al. (2021). COVID-19
835 immune features revealed by a large-scale single-cell transcriptome atlas. *Cell* 184, 1895–1913.e19.

836 52. Ramesh, A., Schubert, R.D., Greenfield, A.L., Dandekar, R., Loudermilk, R., Sabatino, J.J., Koelzer, M.T., Tran,
837 E.B., Koshal, K., Kim, K., et al. (2020). A pathogenic and clonally expanded B cell transcriptome in active multiple
838 sclerosis. *Proc. Natl. Acad. Sci. U. S. A.* 117, 22932–22943.

839 53. Wang, P., Yao, L., Luo, M., Zhou, W., Jin, X., Xu, Z., Yan, S., Li, Y., Xu, C., Cheng, R., et al. (2021). Single-cell
840 transcriptome and TCR profiling reveal activated and expanded T cell populations in Parkinson's disease. *Cell*
841 Discovery 7. 10.1038/s41421-021-00280-3.

842 54. Xu, H., and Jia, J. (2021). Single-Cell RNA Sequencing of Peripheral Blood Reveals Immune Cell Signatures in
843 Alzheimer's Disease. *Front. Immunol.* 12, 645666.

844 55. Zheng, W., Wang, X., Liu, J., Yu, X., Li, L., Wang, H., Yu, J., Pei, X., Li, C., Wang, Z., et al. (2022). Single-cell
845 analyses highlight the proinflammatory contribution of C1q-high monocytes to Behçet's disease. *Proc. Natl. Acad.*
846 *Sci. U. S. A.* 119, e2204289119.

847 56. Boland, B.S., He, Z., Tsai, M.S., Olvera, J.G., Omilusik, K.D., Duong, H.G., Kim, E.S., Limary, A.E., Jin, W.,
848 Milner, J.J., et al. (2020). Heterogeneity and clonal relationships of adaptive immune cells in ulcerative colitis
849 revealed by single-cell analyses. *Sci. Immunol.* 5, eabb4432.

850 57. Tran, V., Papalexis, E., Schroeder, S., Kim, G., Sapre, A., Pangallo, J., Sova, A., Matulich, P., Kenyon, L., Sayar, Z.,
851 et al. (2022). High sensitivity single cell RNA sequencing with split pool barcoding. *bioRxiv*, 2022.08.27.505512.
852 10.1101/2022.08.27.505512.

853 58. Hao, Y., Hao, S., Andersen-Nissen, E., Mauck, W.M., Zheng, S., Butler, A., Lee, M.J., Wilk, A.J., Darby, C., Zager,
854 M., et al. (2021). Integrated analysis of multimodal single-cell data. *Cell* 184, 3573–3587.e29.

855 59. Schmidt, D., Goronzy, J.J., and Weyand, C.M. (1996). CD4+ CD7- CD28- T cells are expanded in rheumatoid
856 arthritis and are characterized by autoreactivity. *J. Clin. Invest.* 97, 2027–2037.

857 60. Fasth, A.E.R., Cao, D., van Vollenhoven, R., Trollmo, C., and Malmström, V. (2004). CD28nullCD4+ T cells--
858 characterization of an effector memory T-cell population in patients with rheumatoid arthritis. *Scand. J. Immunol.*
859 60, 199–208.

860 61. Raveney, B.J.E., Sato, W., Takewaki, D., Zhang, C., Kanazawa, T., Lin, Y., Okamoto, T., Araki, M., Kimura, Y., Sato,
861 N., et al. (2021). Involvement of cytotoxic Eomes-expressing CD4⁺ T cells in secondary progressive multiple
862 sclerosis. *Proc. Natl. Acad. Sci. U. S. A.* 118. 10.1073/pnas.2021818118.

863 62. Funderburg, N.T., Stubblefield Park, S.R., Sung, H.C., Hardy, G., Clagett, B., Ignatz-Hoover, J., Harding, C.V., Fu,
864 P., Katz, J.A., Lederman, M.M., et al. (2013). Circulating CD4(+) and CD8(+) T cells are activated in inflammatory
865 bowel disease and are associated with plasma markers of inflammation. *Immunology* 140, 87–97.

866 63. Xie, Z., Huang, Y., Li, X., Lun, Y., Li, X., He, Y., Wu, S., Wang, S., Sun, J., and Zhang, J. (2022). Atlas of
867 circulating immune cells in Kawasaki disease. *Int. Immunopharmacol.* 102, 108396.

868 64. Knoop, J., Gavrisan, A., Kuehn, D., Reinhardt, J., Heinrich, M., Hippich, M., Eugster, A., Ockert, C., Ziegler, A.-G.,
869 and Bonifacio, E. (2018). GM-CSF producing autoreactive CD4+ T cells in type 1 diabetes. *Clin. Immunol.* *188*,
870 23–30.

871 65. Zhang, Q., Bastard, P., Liu, Z., Le Pen, J., Moncada-Velez, M., Chen, J., Ogishi, M., Sabli, I.K.D., Hodeib, S., Korol,
872 C., et al. (2020). Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. *Science* *370*,
873 eabd4570.

874 66. Banchereau, J., and Pascual, V. (2006). Type I interferon in systemic lupus erythematosus and other autoimmune
875 diseases. *Immunity* *25*, 383–392.

876 67. Yao, Y., Liu, Z., Jallal, B., Shen, N., and Rönnblom, L. (2013). Type I interferons in Sjögren's syndrome.
877 *Autoimmun. Rev.* *12*, 558–566.

878 68. Apaolaza, P.S., Balcacean, D., Zapardiel-Gonzalo, J., Nelson, G., Lenchik, N., Akhbari, P., Gerling, I., Richardson,
879 S.J., Rodriguez-Calvo, T., and nPOD-Virus Group (2021). Islet expression of type I interferon response sensors is
880 associated with immune infiltration and viral infection in type 1 diabetes. *Sci. Adv.* *7*, eabd6527.

881 69. Wang, Z., Wang, W., Chen, Y., and Wei, D. (2012). T helper type 17 cells expand in patients with myasthenia-
882 associated thymoma. *Scand. J. Immunol.* *76*, 54–61.

883 70. Jones, A.P., Trend, S., Byrne, S.N., Fabis-Pedrini, M.J., Geldenhuys, S., Nolan, D., Booth, D.R., Carroll, W.M.,
884 Lucas, R.M., Kermode, A.G., et al. (2017). Altered regulatory T-cell fractions and Helios expression in clinically
885 isolated syndrome: clues to the development of multiple sclerosis. *Clin. Transl. Immunology* *6*, e143.

886 71. Kleinewietfeld, M., and Hafler, D.A. (2013). The plasticity of human Treg and Th17 cells and its role in
887 autoimmunity. *Semin. Immunol.* *25*, 305–312.

888 72. Kanai, Y., Satoh, T., Igawa, K., and Yokozeki, H. (2012). Impaired expression of Tim-3 on Th17 and Th1 cells in
889 psoriasis. *Acta Derm. Venereol.* *92*, 367–371.

890 73. Christodoulou, M.I., Kapsogeorgou, E.K., Moutsopoulos, N.M., and Moutsopoulos, H.M. (2008). Foxp3+ T-
891 regulatory cells in sjögren's syndrome. *Am. J. Pathol.* *173*, 1389–1396.

892 74. Mogilenko, D.A., Shchukina, I., and Artyomov, M.N. (2022). Immune ageing at single-cell resolution. *Nat. Rev.
893 Immunol.* *22*, 484–498.

894 75. Klein, S.L., and Flanagan, K.L. (2016). Sex differences in immune responses. *Nat. Rev. Immunol.* *16*, 626–638.

895 76. Pido-Lopez, J., Imami, N., and Aspinall, R. (2001). Both age and gender affect thymic output: more recent thymic
896 migrants in females than males as they age. *Clin. Exp. Immunol.* *125*, 409–413.

897 77. Abdullah, M., Chai, P.-S., Chong, M.-Y., Tohit, E.R.M., Ramasamy, R., Pei, C.P., and Vidyadar, S. (2012).
898 Gender effect on in vitro lymphocyte subset levels of healthy individuals. *Cell. Immunol.* *272*, 214–219.

899 78. Søndergaard, J.N., Tulyeu, J., Edahiro, R., Shirai, Y., Yamaguchi, Y., Murakami, T., Morita, T., Kato, Y., Hirata, H.,
900 Takeda, Y., et al. (2023). A sex-biased imbalance between Tfr, Tph, and atypical B cells determines antibody
901 responses in COVID-19 patients. *Proc. Natl. Acad. Sci. U. S. A.* *120*, e2217902120.

902 79. González-Amaro, R., Cortés, J.R., Sánchez-Madrid, F., and Martín, P. (2013). Is CD69 an effective brake to control
903 inflammatory diseases? *Trends Mol. Med.* *19*, 625–632.

904 80. Okubo, Y., Torrey, H., Butterworth, J., Zheng, H., and Faustman, D.L. (2016). Treg activation defect in type 1
905 diabetes: correction with TNFR2 agonism. *Clin Transl Immunology* *5*, e56.

906 81. Huang, J., Khademi, M., Fugger, L., Lindhe, Ö., Novakova, L., Axelsson, M., Malmeström, C., Constantinescu, C.,
907 Lycke, J., Piehl, F., et al. (2020). Inflammation-related plasma and CSF biomarkers for multiple sclerosis. *Proc. Natl.
908 Acad. Sci. U. S. A.* *117*, 12952–12960.

909 82. Zhang, M.J., Hou, K., Dey, K.K., Sakaue, S., Jagadeesh, K.A., Weinand, K., Taychameekiatchai, A., Rao, P., Pisco,
910 A.O., Zou, J., et al. (2022). Polygenic enrichment distinguishes disease associations of individual cells in single-cell
911 RNA-seq data. *Nat. Genet.*, 1–9.

912 83. Finucane, H.K., Bulik-Sullivan, B., Gusev, A., Trynka, G., Reshef, Y., Loh, P.R., Anttila, V., Xu, H., Zang, C., Farh, K., et al. (2015). Partitioning heritability by functional annotation using genome-wide association summary statistics. *Nat. Genet.* *47*, 1228–1235.

915 84. Kanai, M., Akiyama, M., Takahashi, A., Matoba, N., Momozawa, Y., Ikeda, M., Iwata, N., Ikegawa, S., Hirata, M., Matsuda, K., et al. (2018). Genetic analysis of quantitative traits in the Japanese population links cell types to complex human diseases. *Nat. Genet.* *50*, 390–400.

918 85. Jagadeesh, K.A., Dey, K.K., Montoro, D.T., Mohan, R., Gazal, S., Engreitz, J.M., Xavier, R.J., Price, A.L., and Regev, A. (2022). Identifying disease-critical cell types and cellular processes by integrating single-cell RNA-sequencing and human genetics. *Nat. Genet.*, 1–14.

921 86. Song, Y., Zhou, L., Miao, F., Chen, G., Zhu, Y., Gao, X., Wang, Y., Pang, L., Zhao, C., Sun, X., et al. (2016). Increased frequency of thymic T follicular helper cells in myasthenia gravis patients with thymoma. *J. Thorac. Dis.* *8*, 314–322.

924 87. Villegas, J.A., Bayer, A.C., Ider, K., Bismuth, J., Truffault, F., Roussin, R., Santelmo, N., Le Panse, R., Berrih-Aknin, S., and Dragin, N. (2019). IL-23/Th17 cell pathway: A promising target to alleviate thymic inflammation maintenance in myasthenia gravis. *J. Autoimmun.* *98*, 59–73.

927 88. Nylander, A., and Hafler, D.A. (2012). Multiple sclerosis. *J. Clin. Invest.* *122*, 1180–1188.

928 89. Hasan, Z., Koizumi, S.-I., Sasaki, D., Yamada, H., Arakaki, N., Fujihara, Y., Okitsu, S., Shirahata, H., and Ishikawa, H. (2017). JunB is essential for IL-23-dependent pathogenicity of Th17 cells. *Nat. Commun.* *8*, 15628.

930 90. Viglietta, V., Baecher-Allan, C., Weiner, H.L., and Hafler, D.A. (2004). Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. *J. Exp. Med.* *199*, 971–979.

932 91. Psarras, A., Wittmann, M., and Vital, E.M. (2022). Emerging concepts of type I interferons in SLE pathogenesis and therapy. *Nat. Rev. Rheumatol.* *18*, 575–590.

934 92. Fueyo-González, F., McGinty, M., Ningoo, M., Anderson, L., Cantarelli, C., Andrea Angeletti, Demir, M., Llaudó, I., Purroy, C., Marjanovic, N., et al. (2022). Interferon- β acts directly on T cells to prolong allograft survival by enhancing regulatory T cell induction through Foxp3 acetylation. *Immunity* *55*, 459–474.e7.

937 93. Brinkmann, V., Geiger, T., Alkan, S., and Heusser, C.H. (1993). Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells. *J. Exp. Med.* *178*, 1655–1663.

939 94. Le Coz, C., Oldridge, D.A., Herati, R.S., De Luna, N., Garifallou, J., Cruz Cabrera, E., Belman, J.P., Pueschl, D., Silva, L.V., Knox, A.V.C., et al. (2023). Human T follicular helper clones seed the germinal center-resident regulatory pool. *Sci. Immunol.* *8*, eade8162.

942 95. Jacobsen, J.T., Hu, W., R. Castro, T.B., Solem, S., Galante, A., Lin, Z., Allon, S.J., Mesin, L., Bilate, A.M., Schiepers, A., et al. (2021). Expression of Foxp3 by T follicular helper cells in end-stage germinal centers. *Science* *373*, eabe5146.

945 96. Poon, M.M.L., Caron, D.P., Wang, Z., Wells, S.B., Chen, D., Meng, W., Szabo, P.A., Lam, N., Kubota, M., Matsumoto, R., et al. (2023). Tissue adaptation and clonal segregation of human memory T cells in barrier sites. *Nat. Immunol.* *10*.1038/s41590-022-01395-9.

948 97. Wolf, F.A., Angerer, P., and Theis, F.J. (2018). SCANPY: large-scale single-cell gene expression data analysis. *Genome Biol.* *19*, 15.

950 98. Hiraoka, Y., Yamada, K., Kawasaki, Y., Hirose, H., Matsumoto, Y., Ishikawa, K., and Yasumizu, Y. (2019). ikra : RNAseq pipeline centered on Salmon. *10.5281/ZENODO.3352573*.

952 99. Krueger, F., James, F., Ewels, P., Afyounian, E., and Schuster-Boeckler, B. (2021). FelixKrueger/TrimGalore: v0.6.7 - DOI via Zenodo *10.5281/zenodo.5127899*.

954 100. Patro, R., Duggal, G., Love, M.I., Irizarry, R.A., and Kingsford, C. (2017). Salmon provides fast and bias-aware quantification of transcript expression. *Nat. Methods* *14*, 417–419.

956 101. Soneson, C., Love, M.I., and Robinson, M.D. (2015). Differential analyses for RNA-seq: transcript-level estimates
957 improve gene-level inferences. *F1000Res.* *4*, 1521.

958 102. Yu, G., Wang, L.-G., Han, Y., and He, Q.-Y. (2012). clusterProfiler: an R Package for Comparing Biological Themes
959 Among Gene Clusters. *OMICS* *16*, 284–287.

960 103. Satija, R., Farrell, J.A., Gennert, D., Schier, A.F., and Regev, A. (2015). Spatial reconstruction of single-cell gene
961 expression data. *Nat. Biotechnol.* *33*, 495–502.

962 104. Sturm, G., Szabo, T., Fotakis, G., Haider, M., Rieder, D., Trajanoski, Z., and Finotello, F. (2020). Scirpy: a Scanpy
963 extension for analyzing single-cell T-cell receptor-sequencing data. *Bioinformatics* *36*, 4817–4818.

964 105. Ke, G., Meng, Q., Finley, T., Wang, T., Chen, W., Ma, W., Ye, Q., Liu, T.-Y., Research, M., University, P., et al.
965 LightGBM: A highly efficient gradient Boosting Decision Tree.
966 <https://papers.nips.cc/paper/2017/file/6449f44a102fde848669bdd9eb6b76fa-Paper.pdf>.

967

968 **Supplementary Note - The applications of NMFproj -**

969 Miyara classification (bulk RNA-seq)

970 We utilized NMFproj to bulk RNA-seq data of sorted peripheral CD4⁺ T cells for each fraction in the Miyara
971 classification³⁰, which classifies CD4⁺ T cells by CD25 and CD45RA (Figure S3E, POH: 0.542). Consistent with
972 previous findings³⁰, Fr. I and Fr. II exhibited high NMF1 (Treg-F), while Fr. V and Fr. IV showed low NMF1 (Treg-F).
973 Similarly, NMF3 (Naive-F) was found to be high in Fr. I and Fr. VI, and low in Fr. II and Fr. V, which also aligns with
974 existing knowledge. Furthermore, Fr. III has been reported to possess weak suppressive activity and a Th17-like
975 phenotype³⁰, and this was concordant with our observation that NMF1 (Treg-F) was lower in Fr. III compared to Fr. I
976 and Fr. II, and NMF2 (Th17-F) was higher.

977 Tph cells (bulk RNA-seq)

978 Profiling of sorted Tph cells also revealed that Tph is a population with both Tfhnness (NMF6) and Th1ness (NMF11)
979 (Figure S3F, POH: 0.134).

980 iTreg cells (bulk RNA-seq)

981 When we applied NMFproj to *in vitro* induced Tregs (iTregs)³¹, NMF1 (Treg-F) was higher in iTreg cells than iTreg
982 cells (Figure S3G). iTreg cells made in conditions to stabilize Treg function with CD28 depletion and two times resting
983 showed higher NMF1 (Treg-F) than other iTreg cells concordantly with the experimentally measured suppressive
984 functions. This suggests that NMFproj can be used for the evaluation of Tregness in a genome-wide manner rather than
985 the tracing of single or a few genes, as performed in most studies, as well as monitoring of unwanted polarization.

986 Pan-cancer CD4⁺ T cells (scRNA-seq)

987 We analyzed scRNA-seq of the pan-cancer CD4⁺ T cell dataset¹⁵ by utilizing NMFproj (Figure S4A; POH: 0.53). The
988 12 factors were also conserved in the tumor microenvironments. Most Treg cells possessed high NMF5 (TregEff/Th2-F),
989 indicating Treg activation in tumor environments. NMF10 (Tissue-F) was broadly high in tumor CD4⁺ T cells.

990 Mouse splenocytes (scRNA-seq)

991 Single-cell data from mouse splenocytes³³ were analyzed to confirm whether cross-species projection was possible. We
992 found that NMFproj could capture not only relatively large populations of Treg and Tfhn but also small populations such
993 as Th17 and Th2, which were not indicated in the original paper (Figure S4B, POH: 0.394). This result indicates that
994 cross-species projection is also possible and, moreover, that NMFproj is informative even for single-cell data with a
995 small number of cells.


996 Cross-tissue immune cells (scRNA-seq)

997 We reanalyzed the single-cell cross-tissue dataset ³² to investigate how the gene features created using peripheral blood
998 would behave in organs (Figure S5). The projected cell features were concordant with the defined cell population, except
999 for the absence of cytotoxic CD4⁺ Temra. Then, we noticed that the cytotoxic CD4⁺ Temra was incorrectly defined as a
1000 CD8⁺ T population and part of CD8⁺ T as CD4⁺ T in the original report. We had similar experiences where CD4⁺ T cells
1001 and CD8⁺ T cells were not well separated and embedded as a mixed cluster in single-cell analysis. We hypothesized that
1002 CD4⁺ T and CD8⁺ T use similar genetic programs, examined the POH of each cell type, and found that, surprisingly,
1003 CD8⁺ T cells, innate T cells, and even B cells and myeloid cells marked relatively high POH. When Evar was examined,
1004 CD8⁺ T cells and innate T cells were found to preferentially use NMF0 (cytotoxic-F), while B cells and Myeloid cells
1005 used NMF5 (TregEff/Th2-F). These observations suggested that gene programs were evolutionally developed and
1006 conserved across cell populations. Examination of POH in CD4⁺ T cells by tissue showed that POH was high in
1007 peripheral blood and secondary lymphoid tissues, while POH was low in tissues such as the liver and muscle, suggesting
1008 that the gene features defined using peripheral CD4⁺ T cells do not fully represent the tissue response. In addition, the
1009 Evar of TregEff/Th2-F, Th17-F, and Th1-F were found to be high in tissues, suggesting that polarization is a prominent
1010 event in tissues.


1011 Sorted CD4⁺ T cell fractions from autoimmune patients (bulk RNA-seq)

1012 NMFproj was adapted to the ImmuNexUT dataset ³⁵, which contains sorted CD4⁺ T cell fractions across autoimmune
1013 diseases to capture qualitative changes in each CD4⁺ T cell population (Figure S6 POH: 0.586). The most prominent
1014 variation is NMF7 (IFN-F), which is elevated across cell types in SLE and MCTD. Also, Tregness (NMF1) decreased in
1015 SLE in naive Treg, indicating Treg dysfunction in SLE patients.


A




C




D




B




E





G




H




I




J



K



L



M




Figure 1





Figure 2

A

Public PBMC/CD4T scRNAseq
953 individuals, >1.8M CD4⁺T cells


Mapping to our reference
(Symphony)

Meta-analysis
Quantity
(Cell Frequencies)




bioRxiv preprint doi: <https://doi.org/10.1101/2023.05.09.540089>; this version posted May 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.


B




C




D




E



F



H



I





Figure 3

Figure 4









Figure 5




Sup Figure 1


A




B




C



D




Sup Figure 2




Sup Figure 3

A




B




Sup Figure 4


A




B




C




D




F



E




G




Sup Figure 5

A





B




Sup Figure 6


A




C



D




B








Sup Figure 7

bioRxiv preprint doi: <https://doi.org/10.1101/2023.05.09.540089>; this version posted May 10, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.




■ diseaseSLE ■ sexfemale ■ diseaseRA ■ diseaseSS ■ diseaseCD
 ■ age ■ diseaseMS ■ diseaseMG ■ diseasePsoriasis ■ diseaseT1D
 ■ diseaseCOVID-19 ■ diseaseNeurosarco. ■ diseaseParkinsonDis. ■ diseaseTuberculosis ■ diseaseUC







COVID-19




Inflammatory disease




Autoimmune



COVID-19



Inflammatory disease



Blood

